data_2kxa_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kxa _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 22.5 tp . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.808 0.337 . . . . 0.0 111.036 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -65.22 -48.33 73.71 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.733 -179.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.2 -32.34 63.28 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -68.35 -44.99 74.04 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.724 0.297 . . . . 0.0 110.666 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 95.3 mt -61.67 -51.09 76.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.574 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.73 -42.78 85.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.954 0.407 . . . . 0.0 110.819 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.41 -34.46 90.0 Favored Glycine 0 C--O 1.226 -0.354 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -65.39 -44.31 87.92 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.034 0.445 . . . . 0.0 110.574 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 91.3 mt -65.05 -28.68 45.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.183 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -92.18 -47.23 7.34 Favored 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 112.577 0.584 . . . . 0.0 112.577 -178.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.87 27.98 9.82 Favored Glycine 0 N--CA 1.47 0.956 0 N-CA-C 111.981 -0.448 . . . . 0.0 111.981 -178.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.85 -146.49 1.85 Allowed Glycine 0 CA--C 1.526 0.721 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.454 178.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 24.7 t-105 -49.66 -61.88 1.87 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.89 0.376 . . . . 0.0 111.381 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 19.0 m -49.56 -32.24 12.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.869 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.48 -37.44 78.69 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 53.3 ttp -58.27 -46.49 85.93 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.748 0.308 . . . . 0.0 110.697 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.4 HD13 HG21 ' A' ' 18' ' ' ILE . 84.4 mt -62.58 -49.08 85.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.826 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -55.52 -45.61 77.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.758 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.74 -34.76 89.73 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 75.4 t-105 -62.91 -47.98 80.92 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.705 0.288 . . . . 0.0 110.584 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 . . . . . 0 C--N 1.331 -0.222 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.661 -179.804 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.2 tp . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.797 0.332 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -65.31 -45.52 84.04 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.435 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.38 -32.54 57.73 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.13 -46.76 60.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.721 0.296 . . . . 0.0 110.469 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 91.2 mt -60.4 -52.71 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.659 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.416 ' O ' ' OE2' ' A' ' 11' ' ' GLU . . . -66.37 -42.46 87.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.924 0.392 . . . . 0.0 110.543 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.89 -34.7 90.63 Favored Glycine 0 C--O 1.227 -0.288 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 26.9 t80 -64.16 -45.62 87.63 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.946 0.403 . . . . 0.0 110.74 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 73.8 mt -67.22 -27.39 38.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.243 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.493 ' N ' ' OE1' ' A' ' 11' ' ' GLU . 0.3 OUTLIER -89.43 -46.82 8.43 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -178.314 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.87 29.17 7.62 Favored Glycine 0 N--CA 1.471 0.968 0 N-CA-C 111.913 -0.475 . . . . 0.0 111.913 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.4 -146.12 2.41 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 120.391 -0.909 . . . . 0.0 111.438 179.068 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 34.7 t-105 -50.39 -61.27 2.28 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.766 0.317 . . . . 0.0 111.179 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.8 m -49.34 -33.62 13.87 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.879 0.371 . . . . 0.0 110.843 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.39 -37.22 79.35 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 42.4 ttp -58.15 -47.01 84.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.759 0.314 . . . . 0.0 110.625 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 83.6 mt -62.04 -50.3 80.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.879 -179.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -53.33 -43.27 67.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.811 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.38 -33.96 68.43 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.159 -0.777 . . . . 0.0 111.159 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 70.2 t-105 -66.23 -43.86 85.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.623 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 15.7 m-85 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.243 -179.883 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.5 tp . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.702 0.287 . . . . 0.0 110.487 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -64.5 -46.94 80.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.585 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.08 -32.0 62.39 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.854 -0.899 . . . . 0.0 110.854 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.34 -47.87 63.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.742 0.306 . . . . 0.0 110.693 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 75.4 mt -61.28 -52.06 65.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.929 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.32 -41.55 93.86 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.006 0.431 . . . . 0.0 110.583 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.52 -35.34 91.91 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.2 t80 -64.43 -44.69 90.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.039 0.447 . . . . 0.0 110.508 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 89.9 mt -64.26 -29.39 47.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.25 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mm-40 -92.22 -46.54 7.68 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -178.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.16 28.16 9.49 Favored Glycine 0 N--CA 1.469 0.848 0 N-CA-C 112.248 -0.341 . . . . 0.0 112.248 -178.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.32 -146.05 1.68 Allowed Glycine 0 CA--C 1.523 0.539 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.35 179.083 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 26.3 t-105 -50.13 -60.71 2.69 Favored 'General case' 0 C--N 1.323 -0.585 0 O-C-N 122.514 -0.404 . . . . 0.0 111.249 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.4 m -49.0 -31.68 7.9 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.011 0.434 . . . . 0.0 110.825 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.27 -37.37 71.17 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' MET . . . . . 0.418 ' C ' ' SD ' ' A' ' 17' ' ' MET . 12.8 tmm? -58.19 -48.44 80.3 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.692 0.282 . . . . 0.0 110.887 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.404 HD11 HG22 ' A' ' 18' ' ' ILE . 86.1 mt -62.04 -53.22 50.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.265 -179.718 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -51.13 -44.81 61.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.907 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.2 -32.74 72.72 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 67.0 t-105 -63.81 -50.46 68.85 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.765 0.317 . . . . 0.0 110.692 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.352 179.988 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.1 tp . . . . . 0 N--CA 1.452 -0.362 0 CA-C-O 120.848 0.356 . . . . 0.0 111.038 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -63.68 -45.97 87.64 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.831 0.348 . . . . 0.0 110.93 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.81 -33.64 68.71 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -66.67 -44.8 80.83 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.737 0.303 . . . . 0.0 110.76 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 87.0 mt -60.25 -52.6 59.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.797 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.47 -41.67 96.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.483 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.62 -35.59 92.06 Favored Glycine 0 C--O 1.225 -0.414 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.5 t80 -64.29 -43.94 93.2 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.1 0.476 . . . . 0.0 110.616 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 88.3 mt -65.9 -29.48 47.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.923 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.4 mm-40 -92.47 -50.68 5.5 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 112.403 0.52 . . . . 0.0 112.403 -177.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.34 28.97 9.09 Favored Glycine 0 N--CA 1.466 0.664 0 CA-C-N 116.387 -0.369 . . . . 0.0 112.405 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 42.89 -143.72 1.36 Allowed Glycine 0 CA--C 1.525 0.674 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.682 178.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 35.2 t-105 -51.15 -59.73 3.87 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 122.55 -0.382 . . . . 0.0 111.008 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 15.7 m -50.11 -34.04 20.68 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.86 -179.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.11 -37.76 63.77 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 37.7 ttp -57.23 -46.45 82.96 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.416 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 92.9 mt -64.1 -50.03 78.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.022 -179.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -54.23 -41.4 68.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.704 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.69 -33.81 66.84 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 74.1 t-105 -62.85 -49.7 73.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.768 0.318 . . . . 0.0 110.497 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 55.4 m-85 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.675 -179.511 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 57.9 tp . . . . . 0 N--CA 1.453 -0.3 0 CA-C-O 120.701 0.286 . . . . 0.0 110.957 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -63.17 -47.87 80.83 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.672 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.26 -34.39 67.37 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.3 -47.74 69.69 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 122.858 -0.201 . . . . 0.0 110.783 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 94.3 mt -59.55 -53.16 52.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.825 -179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.46 -41.46 93.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.907 0.384 . . . . 0.0 110.614 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.12 -35.19 91.74 Favored Glycine 0 C--O 1.227 -0.313 0 N-CA-C 110.437 -1.065 . . . . 0.0 110.437 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -65.45 -43.56 89.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.981 0.419 . . . . 0.0 110.526 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 86.2 mt -66.51 -26.92 38.72 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.886 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -92.67 -49.11 6.25 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -178.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.412 ' O ' ' N ' ' A' ' 16' ' ' GLY . . . -113.22 31.38 6.74 Favored Glycine 0 N--CA 1.464 0.526 0 C-N-CA 121.682 -0.294 . . . . 0.0 112.385 -178.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 42.19 -143.25 1.2 Allowed Glycine 0 CA--C 1.525 0.656 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.591 178.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 27.7 t-105 -51.18 -63.49 1.11 Allowed 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.778 -0.369 . . . . 0.0 111.445 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.4 m -47.38 -32.87 5.31 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.938 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 12' ' ' GLY . . . -70.59 -37.36 68.22 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' MET . . . . . 0.404 ' C ' ' SD ' ' A' ' 17' ' ' MET . 13.7 tmm? -57.05 -47.27 81.36 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.71 0.29 . . . . 0.0 110.568 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.41 HD13 HG21 ' A' ' 18' ' ' ILE . 96.0 mt -62.17 -51.91 66.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.798 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -50.47 -47.05 57.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 -179.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.17 -34.53 86.39 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 71.4 t-105 -60.99 -53.28 59.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.748 0.309 . . . . 0.0 110.592 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 . . . . . 0 C--N 1.327 -0.413 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.553 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.3 tp . . . . . 0 N--CA 1.454 -0.249 0 CA-C-O 120.735 0.302 . . . . 0.0 111.078 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -63.36 -44.88 93.55 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.693 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.13 -31.6 65.78 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.79 -46.94 64.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.621 0.248 . . . . 0.0 110.636 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 82.2 mt -60.76 -51.81 68.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.698 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.94 -42.21 85.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.902 0.382 . . . . 0.0 110.802 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.09 -33.62 87.73 Favored Glycine 0 C--O 1.227 -0.288 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -66.3 -43.89 85.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.168 0.509 . . . . 0.0 110.634 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 85.2 mt -66.95 -27.35 39.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.143 -179.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -92.65 -48.51 6.56 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -178.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.51 28.48 9.52 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 112.109 -0.396 . . . . 0.0 112.109 -178.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.78 -146.44 1.82 Allowed Glycine 0 CA--C 1.525 0.709 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.476 178.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 30.3 t-105 -50.73 -61.93 1.91 Allowed 'General case' 0 C--N 1.319 -0.758 0 O-C-N 122.481 -0.423 . . . . 0.0 111.192 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.2 m -48.42 -33.43 9.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.797 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.31 -37.55 70.87 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 40.4 ttp -57.21 -49.39 76.16 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.706 0.289 . . . . 0.0 110.638 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 92.0 mt -61.01 -50.26 81.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.063 -179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -53.01 -42.77 65.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.879 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.1 -34.99 77.09 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 76.0 t-105 -62.11 -48.42 80.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.632 0.254 . . . . 0.0 110.497 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 50.8 m-85 . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.613 -179.888 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 33.0 tp . . . . . 0 N--CA 1.455 -0.176 0 CA-C-O 120.726 0.298 . . . . 0.0 111.065 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -65.58 -47.32 76.16 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.861 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.33 -32.79 57.76 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.04 -45.72 66.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.758 0.313 . . . . 0.0 111.03 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 95.2 mt -59.58 -53.19 51.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.732 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.17 -42.44 93.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.868 0.366 . . . . 0.0 110.676 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.08 -34.37 89.75 Favored Glycine 0 C--O 1.225 -0.418 0 N-CA-C 110.186 -1.165 . . . . 0.0 110.186 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 37.3 t80 -64.71 -43.69 92.65 Favored 'General case' 0 C--O 1.221 -0.406 0 CA-C-O 121.147 0.498 . . . . 0.0 110.45 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 85.1 mt -68.11 -27.0 35.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.148 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -92.33 -48.29 6.75 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 16' ' ' GLY . . . -112.7 28.98 8.49 Favored Glycine 0 N--CA 1.467 0.749 0 N-CA-C 112.118 -0.393 . . . . 0.0 112.118 -178.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.2 -145.4 1.77 Allowed Glycine 0 CA--C 1.527 0.823 0 C-N-CA 120.562 -0.828 . . . . 0.0 111.453 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 29.9 t-105 -50.72 -60.32 3.17 Favored 'General case' 0 C--N 1.32 -0.701 0 O-C-N 122.467 -0.431 . . . . 0.0 111.307 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 90.4 m -50.07 -33.52 18.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.561 -0.291 . . . . 0.0 110.957 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 12' ' ' GLY . . . -70.23 -36.46 71.01 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 46.4 ttp -58.52 -48.65 80.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.74 0.305 . . . . 0.0 110.709 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.411 HD12 HG22 ' A' ' 18' ' ' ILE . 89.9 mt -61.93 -50.36 80.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.954 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 2.3 m-20 -54.06 -44.31 70.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.704 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.37 -34.36 84.81 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 63.5 t-105 -62.68 -51.41 67.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.668 0.27 . . . . 0.0 110.591 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 53.8 m-85 . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.694 -179.89 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.527 0.088 0 CA-C-O 120.876 0.37 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -63.1 -42.94 99.7 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.282 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.37 -33.26 65.44 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.51 -46.82 65.66 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.753 0.311 . . . . 0.0 110.478 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 75.9 mt -62.73 -51.19 75.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.841 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.45 -42.1 88.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.91 0.386 . . . . 0.0 110.475 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.26 -34.07 88.97 Favored Glycine 0 CA--C 1.52 0.383 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -65.26 -45.05 86.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.033 0.444 . . . . 0.0 110.505 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 92.5 mt -65.47 -28.66 44.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.246 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 24.3 mm-40 -91.31 -47.89 7.23 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -178.309 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.62 27.72 10.23 Favored Glycine 0 N--CA 1.469 0.871 0 N-CA-C 112.118 -0.393 . . . . 0.0 112.118 -178.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.84 -147.05 2.46 Favored Glycine 0 CA--C 1.524 0.628 0 C-N-CA 120.578 -0.82 . . . . 0.0 111.251 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.1 t-105 -50.61 -60.0 3.48 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.91 0.386 . . . . 0.0 111.321 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.3 m -50.66 -31.52 16.5 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.663 -179.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.78 -36.24 66.31 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' MET . . . . . 0.408 ' C ' ' SD ' ' A' ' 17' ' ' MET . 13.4 tmm? -59.21 -47.85 83.8 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.718 0.294 . . . . 0.0 110.834 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.401 HD13 HG21 ' A' ' 18' ' ' ILE . 90.2 mt -62.5 -50.36 80.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.889 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -54.5 -41.68 69.9 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.727 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.08 -33.6 74.54 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -61.79 -48.31 81.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.799 0.333 . . . . 0.0 110.578 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.629 -179.902 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 59.4 tp . . . . . 0 N--CA 1.451 -0.375 0 CA-C-O 120.862 0.363 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -64.56 -46.95 80.57 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.769 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.14 -33.47 61.12 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -68.49 -46.13 70.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.707 0.289 . . . . 0.0 110.757 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.5 mt -61.87 -51.8 68.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.837 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.31 -42.68 92.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.962 0.41 . . . . 0.0 110.619 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.64 -36.3 93.06 Favored Glycine 0 C--O 1.225 -0.411 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 40.2 t80 -62.72 -44.11 97.07 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.076 0.465 . . . . 0.0 110.746 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 87.8 mt -67.62 -27.78 39.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.927 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -89.61 -50.06 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -178.055 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.78 31.98 6.06 Favored Glycine 0 N--CA 1.464 0.539 0 N-CA-C 112.27 -0.332 . . . . 0.0 112.27 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.23 -145.23 1.83 Allowed Glycine 0 CA--C 1.525 0.687 0 C-N-CA 120.618 -0.801 . . . . 0.0 111.628 178.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 30.8 t-105 -50.09 -62.45 1.57 Allowed 'General case' 0 C--N 1.32 -0.678 0 O-C-N 122.605 -0.35 . . . . 0.0 111.296 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.4 m -49.73 -35.34 21.76 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.849 0.357 . . . . 0.0 110.956 -179.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.54 -37.73 93.98 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 36.5 ttp -61.27 -40.94 95.95 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.494 179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.5 mm -61.7 -48.62 87.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.981 -179.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -60.72 -42.61 97.61 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.734 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.03 -37.2 94.56 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 73.9 t-105 -62.13 -45.85 91.62 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.725 0.298 . . . . 0.0 110.507 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 . . . . . 0 C--N 1.327 -0.382 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.715 -179.629 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.7 tp . . . . . 0 N--CA 1.451 -0.425 0 CA-C-O 120.712 0.292 . . . . 0.0 111.121 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -63.64 -47.85 79.63 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.634 -179.36 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.92 -32.52 66.5 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.18 -46.38 74.13 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.619 0.247 . . . . 0.0 110.657 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.52 -50.84 78.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.718 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.82 -42.45 85.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.625 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.92 -34.14 89.13 Favored Glycine 0 C--O 1.225 -0.459 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.0 t80 -65.35 -44.45 87.66 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.079 0.466 . . . . 0.0 110.558 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 89.4 mt -67.07 -27.33 39.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.064 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -91.69 -48.46 6.81 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -178.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 16' ' ' GLY . . . -112.89 30.26 7.55 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 111.998 -0.441 . . . . 0.0 111.998 -178.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.11 -146.23 1.52 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.478 178.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 28.8 t-105 -50.59 -61.82 1.96 Allowed 'General case' 0 C--N 1.32 -0.717 0 O-C-N 122.488 -0.419 . . . . 0.0 111.364 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.0 m -49.11 -32.35 9.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.775 -179.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 12' ' ' GLY . . . -70.73 -36.14 66.72 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 46.5 ttp -58.85 -45.35 90.29 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.756 0.312 . . . . 0.0 110.567 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 79.8 mt -63.9 -50.91 75.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.005 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -52.77 -41.98 64.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.721 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.43 -34.48 74.2 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 68.8 t-105 -63.34 -48.76 76.64 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.687 0.28 . . . . 0.0 110.535 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.629 -179.549 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 22.5 tp -61.04 -45.58 94.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.808 0.337 . . . . 0.0 111.036 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -65.22 -48.33 73.71 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.733 -179.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.2 -32.34 63.28 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -68.35 -44.99 74.04 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.724 0.297 . . . . 0.0 110.666 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 95.3 mt -61.67 -51.09 76.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.574 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.73 -42.78 85.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.954 0.407 . . . . 0.0 110.819 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.41 -34.46 90.0 Favored Glycine 0 C--O 1.226 -0.354 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -65.39 -44.31 87.92 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.034 0.445 . . . . 0.0 110.574 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 91.3 mt -65.05 -28.68 45.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.183 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -92.18 -47.23 7.34 Favored 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 112.577 0.584 . . . . 0.0 112.577 -178.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.87 27.98 9.82 Favored Glycine 0 N--CA 1.47 0.956 0 N-CA-C 111.981 -0.448 . . . . 0.0 111.981 -178.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.85 -146.49 1.85 Allowed Glycine 0 CA--C 1.526 0.721 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.454 178.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 24.7 t-105 -49.66 -61.88 1.87 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.89 0.376 . . . . 0.0 111.381 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 19.0 m -49.56 -32.24 12.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.869 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.48 -37.44 78.69 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 53.3 ttp -58.27 -46.49 85.93 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.748 0.308 . . . . 0.0 110.697 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.4 HD13 HG21 ' A' ' 18' ' ' ILE . 84.4 mt -62.58 -49.08 85.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.826 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -55.52 -45.61 77.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.758 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.74 -34.76 89.73 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 75.4 t-105 -62.91 -47.98 80.92 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.705 0.288 . . . . 0.0 110.584 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 -77.57 -33.04 54.1 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.661 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.29 -87.88 0.7 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 50.1 m . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 118.079 -0.962 . . . . 0.0 110.621 -179.996 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.296 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.2 tp -64.57 -52.21 58.78 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.797 0.332 . . . . 0.0 110.613 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -65.31 -45.52 84.04 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.435 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.38 -32.54 57.73 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.13 -46.76 60.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.721 0.296 . . . . 0.0 110.469 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 91.2 mt -60.4 -52.71 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.659 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.416 ' O ' ' OE2' ' A' ' 11' ' ' GLU . . . -66.37 -42.46 87.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.924 0.392 . . . . 0.0 110.543 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.89 -34.7 90.63 Favored Glycine 0 C--O 1.227 -0.288 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 26.9 t80 -64.16 -45.62 87.63 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.946 0.403 . . . . 0.0 110.74 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 73.8 mt -67.22 -27.39 38.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.243 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.493 ' N ' ' OE1' ' A' ' 11' ' ' GLU . 0.3 OUTLIER -89.43 -46.82 8.43 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -178.314 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.87 29.17 7.62 Favored Glycine 0 N--CA 1.471 0.968 0 N-CA-C 111.913 -0.475 . . . . 0.0 111.913 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.4 -146.12 2.41 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 120.391 -0.909 . . . . 0.0 111.438 179.068 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 34.7 t-105 -50.39 -61.27 2.28 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.766 0.317 . . . . 0.0 111.179 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.8 m -49.34 -33.62 13.87 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.879 0.371 . . . . 0.0 110.843 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.39 -37.22 79.35 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 42.4 ttp -58.15 -47.01 84.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.759 0.314 . . . . 0.0 110.625 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 83.6 mt -62.04 -50.3 80.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.879 -179.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -53.33 -43.27 67.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.811 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.38 -33.96 68.43 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.159 -0.777 . . . . 0.0 111.159 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 70.2 t-105 -66.23 -43.86 85.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.623 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . 0.502 ' O ' ' N ' ' A' ' 24' ' ' SER . 15.7 m-85 -73.65 -24.57 60.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.243 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.23 78.45 0.01 OUTLIER Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' SER . . . . . 0.502 ' N ' ' O ' ' A' ' 22' ' ' TYR . 31.6 t . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 117.877 -1.059 . . . . 0.0 110.527 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.187 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.5 tp -67.79 -49.88 60.01 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.954 -0.298 . . . . 0.0 110.487 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -64.5 -46.94 80.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.585 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.08 -32.0 62.39 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.854 -0.899 . . . . 0.0 110.854 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.34 -47.87 63.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.742 0.306 . . . . 0.0 110.693 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 75.4 mt -61.28 -52.06 65.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.929 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.32 -41.55 93.86 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.006 0.431 . . . . 0.0 110.583 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.52 -35.34 91.91 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.2 t80 -64.43 -44.69 90.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.039 0.447 . . . . 0.0 110.508 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 89.9 mt -64.26 -29.39 47.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.25 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mm-40 -92.22 -46.54 7.68 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -178.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.16 28.16 9.49 Favored Glycine 0 N--CA 1.469 0.848 0 N-CA-C 112.248 -0.341 . . . . 0.0 112.248 -178.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.32 -146.05 1.68 Allowed Glycine 0 CA--C 1.523 0.539 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.35 179.083 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 26.3 t-105 -50.13 -60.71 2.69 Favored 'General case' 0 C--N 1.323 -0.585 0 O-C-N 122.514 -0.404 . . . . 0.0 111.249 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.4 m -49.0 -31.68 7.9 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.011 0.434 . . . . 0.0 110.825 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.27 -37.37 71.17 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.418 ' C ' ' SD ' ' A' ' 17' ' ' MET . 12.8 tmm? -58.19 -48.44 80.3 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.692 0.282 . . . . 0.0 110.887 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.404 HD11 HG22 ' A' ' 18' ' ' ILE . 86.1 mt -62.04 -53.22 50.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.265 -179.718 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -51.13 -44.81 61.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.907 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.2 -32.74 72.72 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 67.0 t-105 -63.81 -50.46 68.85 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.765 0.317 . . . . 0.0 110.692 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -75.23 -28.06 59.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.352 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -53.24 135.54 40.29 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.736 -0.945 . . . . 0.0 110.736 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 32.0 p . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.456 179.871 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.1 tp -60.76 -50.96 71.37 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 120.848 0.356 . . . . 0.0 111.038 -179.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -63.68 -45.97 87.64 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.831 0.348 . . . . 0.0 110.93 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.81 -33.64 68.71 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -66.67 -44.8 80.83 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.737 0.303 . . . . 0.0 110.76 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 87.0 mt -60.25 -52.6 59.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.797 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.47 -41.67 96.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.483 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.62 -35.59 92.06 Favored Glycine 0 C--O 1.225 -0.414 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.5 t80 -64.29 -43.94 93.2 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.1 0.476 . . . . 0.0 110.616 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 88.3 mt -65.9 -29.48 47.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.923 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.4 mm-40 -92.47 -50.68 5.5 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 112.403 0.52 . . . . 0.0 112.403 -177.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.34 28.97 9.09 Favored Glycine 0 N--CA 1.466 0.664 0 CA-C-N 116.387 -0.369 . . . . 0.0 112.405 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 42.89 -143.72 1.36 Allowed Glycine 0 CA--C 1.525 0.674 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.682 178.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 35.2 t-105 -51.15 -59.73 3.87 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 122.55 -0.382 . . . . 0.0 111.008 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 15.7 m -50.11 -34.04 20.68 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.86 -179.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.11 -37.76 63.77 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 37.7 ttp -57.23 -46.45 82.96 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.416 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 92.9 mt -64.1 -50.03 78.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.022 -179.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -54.23 -41.4 68.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.704 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 1' ' ' GLY . . . -70.69 -33.81 66.84 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 74.1 t-105 -62.85 -49.7 73.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.768 0.318 . . . . 0.0 110.497 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 55.4 m-85 -80.88 -33.23 34.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.675 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.82 153.91 2.31 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 17.9 t . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.659 179.932 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 57.9 tp -66.06 -51.69 55.8 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 120.931 -0.308 . . . . 0.0 110.957 -179.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -63.17 -47.87 80.83 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.672 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.26 -34.39 67.37 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.3 -47.74 69.69 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 122.858 -0.201 . . . . 0.0 110.783 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 94.3 mt -59.55 -53.16 52.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.825 -179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.46 -41.46 93.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.907 0.384 . . . . 0.0 110.614 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.12 -35.19 91.74 Favored Glycine 0 C--O 1.227 -0.313 0 N-CA-C 110.437 -1.065 . . . . 0.0 110.437 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -65.45 -43.56 89.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.981 0.419 . . . . 0.0 110.526 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 86.2 mt -66.51 -26.92 38.72 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.886 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -92.67 -49.11 6.25 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -178.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.412 ' O ' ' N ' ' A' ' 16' ' ' GLY . . . -113.22 31.38 6.74 Favored Glycine 0 N--CA 1.464 0.526 0 C-N-CA 121.682 -0.294 . . . . 0.0 112.385 -178.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 42.19 -143.25 1.2 Allowed Glycine 0 CA--C 1.525 0.656 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.591 178.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 27.7 t-105 -51.18 -63.49 1.11 Allowed 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.778 -0.369 . . . . 0.0 111.445 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.4 m -47.38 -32.87 5.31 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.938 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 12' ' ' GLY . . . -70.59 -37.36 68.22 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.404 ' C ' ' SD ' ' A' ' 17' ' ' MET . 13.7 tmm? -57.05 -47.27 81.36 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.71 0.29 . . . . 0.0 110.568 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.41 HD13 HG21 ' A' ' 18' ' ' ILE . 96.0 mt -62.17 -51.91 66.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.798 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -50.47 -47.05 57.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 -179.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.17 -34.53 86.39 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 71.4 t-105 -60.99 -53.28 59.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.748 0.309 . . . . 0.0 110.592 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -75.76 -32.33 59.92 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.553 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.02 -74.44 1.4 Allowed Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 12.1 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.913 -1.042 . . . . 0.0 110.591 179.857 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.171 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.3 tp -66.1 -51.63 56.22 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.735 0.302 . . . . 0.0 111.078 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -63.36 -44.88 93.55 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.693 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.13 -31.6 65.78 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.79 -46.94 64.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.621 0.248 . . . . 0.0 110.636 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 82.2 mt -60.76 -51.81 68.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.698 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.94 -42.21 85.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.902 0.382 . . . . 0.0 110.802 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.09 -33.62 87.73 Favored Glycine 0 C--O 1.227 -0.288 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -66.3 -43.89 85.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.168 0.509 . . . . 0.0 110.634 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 85.2 mt -66.95 -27.35 39.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.143 -179.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -92.65 -48.51 6.56 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -178.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.51 28.48 9.52 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 112.109 -0.396 . . . . 0.0 112.109 -178.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.78 -146.44 1.82 Allowed Glycine 0 CA--C 1.525 0.709 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.476 178.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 30.3 t-105 -50.73 -61.93 1.91 Allowed 'General case' 0 C--N 1.319 -0.758 0 O-C-N 122.481 -0.423 . . . . 0.0 111.192 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.2 m -48.42 -33.43 9.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.797 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.31 -37.55 70.87 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 40.4 ttp -57.21 -49.39 76.16 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.706 0.289 . . . . 0.0 110.638 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 92.0 mt -61.01 -50.26 81.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.063 -179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -53.01 -42.77 65.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.879 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.1 -34.99 77.09 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 76.0 t-105 -62.11 -48.42 80.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.632 0.254 . . . . 0.0 110.497 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 50.8 m-85 -78.06 -31.02 50.02 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.613 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 70.91 -2.39 17.96 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.756 -0.937 . . . . 0.0 110.756 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 90.2 p . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.644 -179.865 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 33.0 tp -62.75 -47.89 81.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.726 0.298 . . . . 0.0 111.065 -179.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -65.58 -47.32 76.16 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.861 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.33 -32.79 57.76 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.04 -45.72 66.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.758 0.313 . . . . 0.0 111.03 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 95.2 mt -59.58 -53.19 51.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.732 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.17 -42.44 93.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.868 0.366 . . . . 0.0 110.676 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.08 -34.37 89.75 Favored Glycine 0 C--O 1.225 -0.418 0 N-CA-C 110.186 -1.165 . . . . 0.0 110.186 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 37.3 t80 -64.71 -43.69 92.65 Favored 'General case' 0 C--O 1.221 -0.406 0 CA-C-O 121.147 0.498 . . . . 0.0 110.45 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 85.1 mt -68.11 -27.0 35.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.148 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -92.33 -48.29 6.75 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 16' ' ' GLY . . . -112.7 28.98 8.49 Favored Glycine 0 N--CA 1.467 0.749 0 N-CA-C 112.118 -0.393 . . . . 0.0 112.118 -178.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.2 -145.4 1.77 Allowed Glycine 0 CA--C 1.527 0.823 0 C-N-CA 120.562 -0.828 . . . . 0.0 111.453 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 29.9 t-105 -50.72 -60.32 3.17 Favored 'General case' 0 C--N 1.32 -0.701 0 O-C-N 122.467 -0.431 . . . . 0.0 111.307 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 90.4 m -50.07 -33.52 18.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.561 -0.291 . . . . 0.0 110.957 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 12' ' ' GLY . . . -70.23 -36.46 71.01 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 46.4 ttp -58.52 -48.65 80.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.74 0.305 . . . . 0.0 110.709 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.411 HD12 HG22 ' A' ' 18' ' ' ILE . 89.9 mt -61.93 -50.36 80.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.954 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 2.3 m-20 -54.06 -44.31 70.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.704 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.37 -34.36 84.81 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 63.5 t-105 -62.68 -51.41 67.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.668 0.27 . . . . 0.0 110.591 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 53.8 m-85 -77.13 -34.36 56.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.694 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.43 36.74 62.87 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.8 m . . . . . 0 C--O 1.222 -0.392 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.494 -179.837 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.121 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -67.42 -56.05 11.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.876 0.37 . . . . 0.0 110.889 -179.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -63.1 -42.94 99.7 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.282 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.37 -33.26 65.44 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.51 -46.82 65.66 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.753 0.311 . . . . 0.0 110.478 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 75.9 mt -62.73 -51.19 75.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.841 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.45 -42.1 88.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.91 0.386 . . . . 0.0 110.475 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.26 -34.07 88.97 Favored Glycine 0 CA--C 1.52 0.383 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -65.26 -45.05 86.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.033 0.444 . . . . 0.0 110.505 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 92.5 mt -65.47 -28.66 44.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.246 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 24.3 mm-40 -91.31 -47.89 7.23 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -178.309 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.62 27.72 10.23 Favored Glycine 0 N--CA 1.469 0.871 0 N-CA-C 112.118 -0.393 . . . . 0.0 112.118 -178.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.84 -147.05 2.46 Favored Glycine 0 CA--C 1.524 0.628 0 C-N-CA 120.578 -0.82 . . . . 0.0 111.251 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 20.1 t-105 -50.61 -60.0 3.48 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.91 0.386 . . . . 0.0 111.321 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.3 m -50.66 -31.52 16.5 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.663 -179.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.78 -36.24 66.31 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' MET . . . . . 0.408 ' C ' ' SD ' ' A' ' 17' ' ' MET . 13.4 tmm? -59.21 -47.85 83.8 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.718 0.294 . . . . 0.0 110.834 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.401 HD13 HG21 ' A' ' 18' ' ' ILE . 90.2 mt -62.5 -50.36 80.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.889 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -54.5 -41.68 69.9 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.727 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.08 -33.6 74.54 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -61.79 -48.31 81.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.799 0.333 . . . . 0.0 110.578 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -70.85 -30.91 67.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.629 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.73 126.03 0.12 Allowed Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 86.7 p . . . . . 0 C--O 1.219 -0.519 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.55 -179.872 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 59.4 tp -64.26 -50.73 66.81 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-O 120.862 0.363 . . . . 0.0 110.895 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -64.56 -46.95 80.57 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.769 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.14 -33.47 61.12 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -68.49 -46.13 70.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.707 0.289 . . . . 0.0 110.757 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.5 mt -61.87 -51.8 68.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.837 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.31 -42.68 92.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.962 0.41 . . . . 0.0 110.619 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.64 -36.3 93.06 Favored Glycine 0 C--O 1.225 -0.411 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 40.2 t80 -62.72 -44.11 97.07 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.076 0.465 . . . . 0.0 110.746 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 87.8 mt -67.62 -27.78 39.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.927 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -89.61 -50.06 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -178.055 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.78 31.98 6.06 Favored Glycine 0 N--CA 1.464 0.539 0 N-CA-C 112.27 -0.332 . . . . 0.0 112.27 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.23 -145.23 1.83 Allowed Glycine 0 CA--C 1.525 0.687 0 C-N-CA 120.618 -0.801 . . . . 0.0 111.628 178.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 30.8 t-105 -50.09 -62.45 1.57 Allowed 'General case' 0 C--N 1.32 -0.678 0 O-C-N 122.605 -0.35 . . . . 0.0 111.296 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.4 m -49.73 -35.34 21.76 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.849 0.357 . . . . 0.0 110.956 -179.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.54 -37.73 93.98 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 36.5 ttp -61.27 -40.94 95.95 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.494 179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.5 mm -61.7 -48.62 87.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.981 -179.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -60.72 -42.61 97.61 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.734 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.03 -37.2 94.56 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 73.9 t-105 -62.13 -45.85 91.62 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.725 0.298 . . . . 0.0 110.507 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -74.34 -34.21 63.35 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.715 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.93 1.1 46.27 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.4 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.97 -1.015 . . . . 0.0 110.613 -179.847 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.7 tp -65.22 -49.55 69.26 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.712 0.292 . . . . 0.0 111.121 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -63.64 -47.85 79.63 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.634 -179.36 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.92 -32.52 66.5 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.18 -46.38 74.13 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.619 0.247 . . . . 0.0 110.657 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.52 -50.84 78.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.718 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.82 -42.45 85.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.625 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.92 -34.14 89.13 Favored Glycine 0 C--O 1.225 -0.459 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.0 t80 -65.35 -44.45 87.66 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.079 0.466 . . . . 0.0 110.558 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 89.4 mt -67.07 -27.33 39.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.064 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -91.69 -48.46 6.81 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -178.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 16' ' ' GLY . . . -112.89 30.26 7.55 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 111.998 -0.441 . . . . 0.0 111.998 -178.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.11 -146.23 1.52 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.478 178.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 28.8 t-105 -50.59 -61.82 1.96 Allowed 'General case' 0 C--N 1.32 -0.717 0 O-C-N 122.488 -0.419 . . . . 0.0 111.364 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.0 m -49.11 -32.35 9.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.775 -179.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 12' ' ' GLY . . . -70.73 -36.14 66.72 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 46.5 ttp -58.85 -45.35 90.29 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.756 0.312 . . . . 0.0 110.567 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 79.8 mt -63.9 -50.91 75.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.005 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -52.77 -41.98 64.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.721 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.43 -34.48 74.2 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 68.8 t-105 -63.34 -48.76 76.64 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.687 0.28 . . . . 0.0 110.535 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -74.2 -31.12 62.52 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.629 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.43 -66.01 1.31 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 12.4 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.037 -0.982 . . . . 0.0 110.586 179.967 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 22.5 tp . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.808 0.337 . . . . 0.0 111.036 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -65.22 -48.33 73.71 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.733 -179.445 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.2 -32.34 63.28 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -68.35 -44.99 74.04 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.724 0.297 . . . . 0.0 110.666 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 95.3 mt -61.67 -51.09 76.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.574 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.73 -42.78 85.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.954 0.407 . . . . 0.0 110.819 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.41 -34.46 90.0 Favored Glycine 0 C--O 1.226 -0.354 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -65.39 -44.31 87.92 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.034 0.445 . . . . 0.0 110.574 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 91.3 mt -65.05 -28.68 45.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.183 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -92.18 -47.23 7.34 Favored 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 112.577 0.584 . . . . 0.0 112.577 -178.339 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.87 27.98 9.82 Favored Glycine 0 N--CA 1.47 0.956 0 N-CA-C 111.981 -0.448 . . . . 0.0 111.981 -178.31 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.85 -146.49 1.85 Allowed Glycine 0 CA--C 1.526 0.721 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.454 178.852 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.444 ' HE1' HD11 ' A' ' 18' ' ' ILE . 24.7 t-105 -49.66 -61.88 1.87 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.89 0.376 . . . . 0.0 111.381 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 19.0 m -49.56 -32.24 12.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.869 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.48 -37.44 78.69 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 53.3 ttp -58.27 -46.49 85.93 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.748 0.308 . . . . 0.0 110.697 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.444 HD11 ' HE1' ' A' ' 14' ' ' TRP . 84.4 mt -62.58 -49.08 85.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.826 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -55.52 -45.61 77.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.758 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.74 -34.76 89.73 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 75.4 t-105 -62.91 -47.98 80.92 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.705 0.288 . . . . 0.0 110.584 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 . . . . . 0 C--N 1.331 -0.222 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.661 -179.804 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.2 tp . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.797 0.332 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -65.31 -45.52 84.04 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.435 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.38 -32.54 57.73 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.13 -46.76 60.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.721 0.296 . . . . 0.0 110.469 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 91.2 mt -60.4 -52.71 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.659 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.416 ' O ' ' OE2' ' A' ' 11' ' ' GLU . . . -66.37 -42.46 87.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.924 0.392 . . . . 0.0 110.543 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.89 -34.7 90.63 Favored Glycine 0 C--O 1.227 -0.288 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 26.9 t80 -64.16 -45.62 87.63 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.946 0.403 . . . . 0.0 110.74 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 73.8 mt -67.22 -27.39 38.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.243 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.493 ' N ' ' OE1' ' A' ' 11' ' ' GLU . 0.3 OUTLIER -89.43 -46.82 8.43 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -178.314 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.87 29.17 7.62 Favored Glycine 0 N--CA 1.471 0.968 0 N-CA-C 111.913 -0.475 . . . . 0.0 111.913 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.4 -146.12 2.41 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 120.391 -0.909 . . . . 0.0 111.438 179.068 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.481 ' HE1' HD11 ' A' ' 18' ' ' ILE . 34.7 t-105 -50.39 -61.27 2.28 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.766 0.317 . . . . 0.0 111.179 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.8 m -49.34 -33.62 13.87 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.879 0.371 . . . . 0.0 110.843 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.39 -37.22 79.35 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 42.4 ttp -58.15 -47.01 84.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.759 0.314 . . . . 0.0 110.625 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.481 HD11 ' HE1' ' A' ' 14' ' ' TRP . 83.6 mt -62.04 -50.3 80.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.879 -179.627 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -53.33 -43.27 67.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.811 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.38 -33.96 68.43 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.159 -0.777 . . . . 0.0 111.159 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 70.2 t-105 -66.23 -43.86 85.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.623 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 15.7 m-85 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.243 -179.883 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.5 tp . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.702 0.287 . . . . 0.0 110.487 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -64.5 -46.94 80.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.585 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.08 -32.0 62.39 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.854 -0.899 . . . . 0.0 110.854 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.34 -47.87 63.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.742 0.306 . . . . 0.0 110.693 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 75.4 mt -61.28 -52.06 65.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.929 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.32 -41.55 93.86 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.006 0.431 . . . . 0.0 110.583 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.52 -35.34 91.91 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.2 t80 -64.43 -44.69 90.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.039 0.447 . . . . 0.0 110.508 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 89.9 mt -64.26 -29.39 47.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.25 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mm-40 -92.22 -46.54 7.68 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -178.27 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.16 28.16 9.49 Favored Glycine 0 N--CA 1.469 0.848 0 N-CA-C 112.248 -0.341 . . . . 0.0 112.248 -178.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.32 -146.05 1.68 Allowed Glycine 0 CA--C 1.523 0.539 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.35 179.083 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.525 ' HE1' HD11 ' A' ' 18' ' ' ILE . 26.3 t-105 -50.13 -60.71 2.69 Favored 'General case' 0 C--N 1.323 -0.585 0 O-C-N 122.514 -0.404 . . . . 0.0 111.249 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.4 m -49.0 -31.68 7.9 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.011 0.434 . . . . 0.0 110.825 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.27 -37.37 71.17 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' MET . . . . . 0.418 ' C ' ' SD ' ' A' ' 17' ' ' MET . 12.8 tmm? -58.19 -48.44 80.3 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.692 0.282 . . . . 0.0 110.887 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.525 HD11 ' HE1' ' A' ' 14' ' ' TRP . 86.1 mt -62.04 -53.22 50.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.265 -179.718 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -51.13 -44.81 61.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.907 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.2 -32.74 72.72 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 67.0 t-105 -63.81 -50.46 68.85 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.765 0.317 . . . . 0.0 110.692 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.352 179.988 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.1 tp . . . . . 0 N--CA 1.452 -0.362 0 CA-C-O 120.848 0.356 . . . . 0.0 111.038 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -63.68 -45.97 87.64 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.831 0.348 . . . . 0.0 110.93 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.81 -33.64 68.71 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -66.67 -44.8 80.83 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.737 0.303 . . . . 0.0 110.76 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 87.0 mt -60.25 -52.6 59.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.797 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.47 -41.67 96.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.483 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.62 -35.59 92.06 Favored Glycine 0 C--O 1.225 -0.414 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.5 t80 -64.29 -43.94 93.2 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.1 0.476 . . . . 0.0 110.616 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 88.3 mt -65.9 -29.48 47.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.923 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.4 mm-40 -92.47 -50.68 5.5 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 112.403 0.52 . . . . 0.0 112.403 -177.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.34 28.97 9.09 Favored Glycine 0 N--CA 1.466 0.664 0 CA-C-N 116.387 -0.369 . . . . 0.0 112.405 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 42.89 -143.72 1.36 Allowed Glycine 0 CA--C 1.525 0.674 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.682 178.451 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.557 ' HE1' HD11 ' A' ' 18' ' ' ILE . 35.2 t-105 -51.15 -59.73 3.87 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 122.55 -0.382 . . . . 0.0 111.008 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 15.7 m -50.11 -34.04 20.68 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.86 -179.426 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.11 -37.76 63.77 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 37.7 ttp -57.23 -46.45 82.96 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.416 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.557 HD11 ' HE1' ' A' ' 14' ' ' TRP . 92.9 mt -64.1 -50.03 78.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.022 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -54.23 -41.4 68.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.704 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.69 -33.81 66.84 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 74.1 t-105 -62.85 -49.7 73.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.768 0.318 . . . . 0.0 110.497 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 55.4 m-85 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.675 -179.511 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 57.9 tp . . . . . 0 N--CA 1.453 -0.3 0 CA-C-O 120.701 0.286 . . . . 0.0 110.957 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -63.17 -47.87 80.83 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.672 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.26 -34.39 67.37 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.3 -47.74 69.69 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 122.858 -0.201 . . . . 0.0 110.783 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 94.3 mt -59.55 -53.16 52.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.825 -179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.46 -41.46 93.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.907 0.384 . . . . 0.0 110.614 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.12 -35.19 91.74 Favored Glycine 0 C--O 1.227 -0.313 0 N-CA-C 110.437 -1.065 . . . . 0.0 110.437 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -65.45 -43.56 89.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.981 0.419 . . . . 0.0 110.526 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 86.2 mt -66.51 -26.92 38.72 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.886 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -92.67 -49.11 6.25 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -178.321 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.22 31.38 6.74 Favored Glycine 0 N--CA 1.464 0.526 0 C-N-CA 121.682 -0.294 . . . . 0.0 112.385 -178.52 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 42.19 -143.25 1.2 Allowed Glycine 0 CA--C 1.525 0.656 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.591 178.468 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.412 ' HE1' HD11 ' A' ' 18' ' ' ILE . 27.7 t-105 -51.18 -63.49 1.11 Allowed 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.778 -0.369 . . . . 0.0 111.445 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.4 m -47.38 -32.87 5.31 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.938 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.59 -37.36 68.22 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' MET . . . . . 0.404 ' C ' ' SD ' ' A' ' 17' ' ' MET . 13.7 tmm? -57.05 -47.27 81.36 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.71 0.29 . . . . 0.0 110.568 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.412 HD11 ' HE1' ' A' ' 14' ' ' TRP . 96.0 mt -62.17 -51.91 66.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.798 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -50.47 -47.05 57.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 -179.603 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.17 -34.53 86.39 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 71.4 t-105 -60.99 -53.28 59.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.748 0.309 . . . . 0.0 110.592 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 . . . . . 0 C--N 1.327 -0.413 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.553 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.3 tp . . . . . 0 N--CA 1.454 -0.249 0 CA-C-O 120.735 0.302 . . . . 0.0 111.078 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -63.36 -44.88 93.55 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.693 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.13 -31.6 65.78 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.79 -46.94 64.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.621 0.248 . . . . 0.0 110.636 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 82.2 mt -60.76 -51.81 68.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.698 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.94 -42.21 85.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.902 0.382 . . . . 0.0 110.802 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.09 -33.62 87.73 Favored Glycine 0 C--O 1.227 -0.288 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -66.3 -43.89 85.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.168 0.509 . . . . 0.0 110.634 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 85.2 mt -66.95 -27.35 39.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.143 -179.276 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -92.65 -48.51 6.56 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -178.618 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.51 28.48 9.52 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 112.109 -0.396 . . . . 0.0 112.109 -178.783 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.78 -146.44 1.82 Allowed Glycine 0 CA--C 1.525 0.709 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.476 178.43 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.502 ' HE1' HD11 ' A' ' 18' ' ' ILE . 30.3 t-105 -50.73 -61.93 1.91 Allowed 'General case' 0 C--N 1.319 -0.758 0 O-C-N 122.481 -0.423 . . . . 0.0 111.192 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.2 m -48.42 -33.43 9.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.797 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.31 -37.55 70.87 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 40.4 ttp -57.21 -49.39 76.16 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.706 0.289 . . . . 0.0 110.638 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.502 HD11 ' HE1' ' A' ' 14' ' ' TRP . 92.0 mt -61.01 -50.26 81.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.063 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -53.01 -42.77 65.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.879 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.1 -34.99 77.09 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 76.0 t-105 -62.11 -48.42 80.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.632 0.254 . . . . 0.0 110.497 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 50.8 m-85 . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.613 -179.888 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 33.0 tp . . . . . 0 N--CA 1.455 -0.176 0 CA-C-O 120.726 0.298 . . . . 0.0 111.065 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -65.58 -47.32 76.16 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.861 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.33 -32.79 57.76 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.668 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.04 -45.72 66.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.758 0.313 . . . . 0.0 111.03 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 95.2 mt -59.58 -53.19 51.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.732 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.17 -42.44 93.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.868 0.366 . . . . 0.0 110.676 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.08 -34.37 89.75 Favored Glycine 0 C--O 1.225 -0.418 0 N-CA-C 110.186 -1.165 . . . . 0.0 110.186 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 37.3 t80 -64.71 -43.69 92.65 Favored 'General case' 0 C--O 1.221 -0.406 0 CA-C-O 121.147 0.498 . . . . 0.0 110.45 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 85.1 mt -68.11 -27.0 35.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.148 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -92.33 -48.29 6.75 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.7 28.98 8.49 Favored Glycine 0 N--CA 1.467 0.749 0 N-CA-C 112.118 -0.393 . . . . 0.0 112.118 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.2 -145.4 1.77 Allowed Glycine 0 CA--C 1.527 0.823 0 C-N-CA 120.562 -0.828 . . . . 0.0 111.453 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.549 ' HE1' HD11 ' A' ' 18' ' ' ILE . 29.9 t-105 -50.72 -60.32 3.17 Favored 'General case' 0 C--N 1.32 -0.701 0 O-C-N 122.467 -0.431 . . . . 0.0 111.307 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 90.4 m -50.07 -33.52 18.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.561 -0.291 . . . . 0.0 110.957 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 -36.46 71.01 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 46.4 ttp -58.52 -48.65 80.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.74 0.305 . . . . 0.0 110.709 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.549 HD11 ' HE1' ' A' ' 14' ' ' TRP . 89.9 mt -61.93 -50.36 80.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.954 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 2.3 m-20 -54.06 -44.31 70.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.704 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.37 -34.36 84.81 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 63.5 t-105 -62.68 -51.41 67.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.668 0.27 . . . . 0.0 110.591 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 53.8 m-85 . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.694 -179.89 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.423 ' O ' HD13 ' A' ' 2' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.527 0.088 0 CA-C-O 120.876 0.37 . . . . 0.0 110.889 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -63.1 -42.94 99.7 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.282 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.37 -33.26 65.44 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.51 -46.82 65.66 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.753 0.311 . . . . 0.0 110.478 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 75.9 mt -62.73 -51.19 75.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.841 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.45 -42.1 88.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.91 0.386 . . . . 0.0 110.475 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.26 -34.07 88.97 Favored Glycine 0 CA--C 1.52 0.383 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -65.26 -45.05 86.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.033 0.444 . . . . 0.0 110.505 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 92.5 mt -65.47 -28.66 44.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.246 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 24.3 mm-40 -91.31 -47.89 7.23 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -178.309 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.62 27.72 10.23 Favored Glycine 0 N--CA 1.469 0.871 0 N-CA-C 112.118 -0.393 . . . . 0.0 112.118 -178.204 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.84 -147.05 2.46 Favored Glycine 0 CA--C 1.524 0.628 0 C-N-CA 120.578 -0.82 . . . . 0.0 111.251 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.514 ' HE1' HD11 ' A' ' 18' ' ' ILE . 20.1 t-105 -50.61 -60.0 3.48 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.91 0.386 . . . . 0.0 111.321 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.3 m -50.66 -31.52 16.5 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.663 -179.589 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.78 -36.24 66.31 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' MET . . . . . 0.408 ' C ' ' SD ' ' A' ' 17' ' ' MET . 13.4 tmm? -59.21 -47.85 83.8 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.718 0.294 . . . . 0.0 110.834 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.514 HD11 ' HE1' ' A' ' 14' ' ' TRP . 90.2 mt -62.5 -50.36 80.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.889 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -54.5 -41.68 69.9 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.727 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.08 -33.6 74.54 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -61.79 -48.31 81.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.799 0.333 . . . . 0.0 110.578 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.629 -179.902 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 59.4 tp . . . . . 0 N--CA 1.451 -0.375 0 CA-C-O 120.862 0.363 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -64.56 -46.95 80.57 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.769 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.14 -33.47 61.12 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -68.49 -46.13 70.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.707 0.289 . . . . 0.0 110.757 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.5 mt -61.87 -51.8 68.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.837 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.31 -42.68 92.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.962 0.41 . . . . 0.0 110.619 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.64 -36.3 93.06 Favored Glycine 0 C--O 1.225 -0.411 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 40.2 t80 -62.72 -44.11 97.07 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.076 0.465 . . . . 0.0 110.746 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 87.8 mt -67.62 -27.78 39.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.927 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -89.61 -50.06 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -178.055 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.78 31.98 6.06 Favored Glycine 0 N--CA 1.464 0.539 0 N-CA-C 112.27 -0.332 . . . . 0.0 112.27 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.23 -145.23 1.83 Allowed Glycine 0 CA--C 1.525 0.687 0 C-N-CA 120.618 -0.801 . . . . 0.0 111.628 178.49 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 30.8 t-105 -50.09 -62.45 1.57 Allowed 'General case' 0 C--N 1.32 -0.678 0 O-C-N 122.605 -0.35 . . . . 0.0 111.296 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.4 m -49.73 -35.34 21.76 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.849 0.357 . . . . 0.0 110.956 -179.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.54 -37.73 93.98 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.709 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 36.5 ttp -61.27 -40.94 95.95 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.494 179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.5 mm -61.7 -48.62 87.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.981 -179.487 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -60.72 -42.61 97.61 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.734 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.03 -37.2 94.56 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 73.9 t-105 -62.13 -45.85 91.62 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.725 0.298 . . . . 0.0 110.507 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 . . . . . 0 C--N 1.327 -0.382 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.715 -179.629 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.7 tp . . . . . 0 N--CA 1.451 -0.425 0 CA-C-O 120.712 0.292 . . . . 0.0 111.121 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -63.64 -47.85 79.63 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.634 -179.36 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.92 -32.52 66.5 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.18 -46.38 74.13 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.619 0.247 . . . . 0.0 110.657 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.52 -50.84 78.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.718 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.82 -42.45 85.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.625 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.92 -34.14 89.13 Favored Glycine 0 C--O 1.225 -0.459 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.0 t80 -65.35 -44.45 87.66 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.079 0.466 . . . . 0.0 110.558 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 89.4 mt -67.07 -27.33 39.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.064 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -91.69 -48.46 6.81 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -178.543 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 16' ' ' GLY . . . -112.89 30.26 7.55 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 111.998 -0.441 . . . . 0.0 111.998 -178.57 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.11 -146.23 1.52 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.478 178.505 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' TRP . . . . . 0.534 ' HE1' HD11 ' A' ' 18' ' ' ILE . 28.8 t-105 -50.59 -61.82 1.96 Allowed 'General case' 0 C--N 1.32 -0.717 0 O-C-N 122.488 -0.419 . . . . 0.0 111.364 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.0 m -49.11 -32.35 9.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.775 -179.269 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 12' ' ' GLY . . . -70.73 -36.14 66.72 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 46.5 ttp -58.85 -45.35 90.29 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.756 0.312 . . . . 0.0 110.567 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.534 HD11 ' HE1' ' A' ' 14' ' ' TRP . 79.8 mt -63.9 -50.91 75.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.005 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -52.77 -41.98 64.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.721 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.43 -34.48 74.2 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 68.8 t-105 -63.34 -48.76 76.64 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.687 0.28 . . . . 0.0 110.535 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.629 -179.549 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 22.5 tp -61.04 -45.58 94.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.808 0.337 . . . . 0.0 111.036 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -65.22 -48.33 73.71 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.733 -179.445 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.2 -32.34 63.28 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -68.35 -44.99 74.04 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.724 0.297 . . . . 0.0 110.666 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 95.3 mt -61.67 -51.09 76.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.574 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.73 -42.78 85.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.954 0.407 . . . . 0.0 110.819 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.41 -34.46 90.0 Favored Glycine 0 C--O 1.226 -0.354 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -65.39 -44.31 87.92 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.034 0.445 . . . . 0.0 110.574 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 91.3 mt -65.05 -28.68 45.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.183 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -92.18 -47.23 7.34 Favored 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 112.577 0.584 . . . . 0.0 112.577 -178.339 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.87 27.98 9.82 Favored Glycine 0 N--CA 1.47 0.956 0 N-CA-C 111.981 -0.448 . . . . 0.0 111.981 -178.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.85 -146.49 1.85 Allowed Glycine 0 CA--C 1.526 0.721 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.454 178.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.444 ' HE1' HD11 ' A' ' 18' ' ' ILE . 24.7 t-105 -49.66 -61.88 1.87 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.89 0.376 . . . . 0.0 111.381 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 19.0 m -49.56 -32.24 12.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.869 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.48 -37.44 78.69 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 53.3 ttp -58.27 -46.49 85.93 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.748 0.308 . . . . 0.0 110.697 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.444 HD11 ' HE1' ' A' ' 14' ' ' TRP . 84.4 mt -62.58 -49.08 85.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.826 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -55.52 -45.61 77.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.758 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.74 -34.76 89.73 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 75.4 t-105 -62.91 -47.98 80.92 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.705 0.288 . . . . 0.0 110.584 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 -77.57 -33.04 54.1 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.661 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.29 -87.88 0.7 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 50.1 m . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 118.079 -0.962 . . . . 0.0 110.621 -179.996 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.296 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.2 tp -64.57 -52.21 58.78 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.797 0.332 . . . . 0.0 110.613 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -65.31 -45.52 84.04 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.435 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.38 -32.54 57.73 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.13 -46.76 60.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.721 0.296 . . . . 0.0 110.469 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 91.2 mt -60.4 -52.71 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.659 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.416 ' O ' ' OE2' ' A' ' 11' ' ' GLU . . . -66.37 -42.46 87.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.924 0.392 . . . . 0.0 110.543 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.89 -34.7 90.63 Favored Glycine 0 C--O 1.227 -0.288 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 26.9 t80 -64.16 -45.62 87.63 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.946 0.403 . . . . 0.0 110.74 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 73.8 mt -67.22 -27.39 38.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.243 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.493 ' N ' ' OE1' ' A' ' 11' ' ' GLU . 0.3 OUTLIER -89.43 -46.82 8.43 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -178.314 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.87 29.17 7.62 Favored Glycine 0 N--CA 1.471 0.968 0 N-CA-C 111.913 -0.475 . . . . 0.0 111.913 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.4 -146.12 2.41 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 120.391 -0.909 . . . . 0.0 111.438 179.068 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.481 ' HE1' HD11 ' A' ' 18' ' ' ILE . 34.7 t-105 -50.39 -61.27 2.28 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.766 0.317 . . . . 0.0 111.179 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.8 m -49.34 -33.62 13.87 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.879 0.371 . . . . 0.0 110.843 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.39 -37.22 79.35 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 42.4 ttp -58.15 -47.01 84.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.759 0.314 . . . . 0.0 110.625 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.481 HD11 ' HE1' ' A' ' 14' ' ' TRP . 83.6 mt -62.04 -50.3 80.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.879 -179.627 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -53.33 -43.27 67.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.811 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.38 -33.96 68.43 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.159 -0.777 . . . . 0.0 111.159 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 70.2 t-105 -66.23 -43.86 85.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.623 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' TYR . . . . . 0.508 ' O ' ' N ' ' A' ' 24' ' ' SER . 15.7 m-85 -73.65 -24.57 60.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.243 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.23 78.45 0.01 OUTLIER Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.508 ' N ' ' O ' ' A' ' 22' ' ' TYR . 31.6 t . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 117.877 -1.059 . . . . 0.0 110.527 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.187 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.5 tp -67.79 -49.88 60.01 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.954 -0.298 . . . . 0.0 110.487 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -64.5 -46.94 80.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.585 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.08 -32.0 62.39 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.854 -0.899 . . . . 0.0 110.854 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.34 -47.87 63.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.742 0.306 . . . . 0.0 110.693 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 75.4 mt -61.28 -52.06 65.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.929 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.32 -41.55 93.86 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.006 0.431 . . . . 0.0 110.583 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.52 -35.34 91.91 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.2 t80 -64.43 -44.69 90.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.039 0.447 . . . . 0.0 110.508 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 89.9 mt -64.26 -29.39 47.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.25 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mm-40 -92.22 -46.54 7.68 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -178.27 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.16 28.16 9.49 Favored Glycine 0 N--CA 1.469 0.848 0 N-CA-C 112.248 -0.341 . . . . 0.0 112.248 -178.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.32 -146.05 1.68 Allowed Glycine 0 CA--C 1.523 0.539 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.35 179.083 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.525 ' HE1' HD11 ' A' ' 18' ' ' ILE . 26.3 t-105 -50.13 -60.71 2.69 Favored 'General case' 0 C--N 1.323 -0.585 0 O-C-N 122.514 -0.404 . . . . 0.0 111.249 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.4 m -49.0 -31.68 7.9 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.011 0.434 . . . . 0.0 110.825 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.27 -37.37 71.17 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.418 ' C ' ' SD ' ' A' ' 17' ' ' MET . 12.8 tmm? -58.19 -48.44 80.3 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.692 0.282 . . . . 0.0 110.887 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.525 HD11 ' HE1' ' A' ' 14' ' ' TRP . 86.1 mt -62.04 -53.22 50.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.265 -179.718 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -51.13 -44.81 61.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.907 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.2 -32.74 72.72 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 67.0 t-105 -63.81 -50.46 68.85 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.765 0.317 . . . . 0.0 110.692 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -75.23 -28.06 59.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.352 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -53.24 135.54 40.29 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.736 -0.945 . . . . 0.0 110.736 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 32.0 p . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.456 179.871 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.1 tp -60.76 -50.96 71.37 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 120.848 0.356 . . . . 0.0 111.038 -179.36 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -63.68 -45.97 87.64 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.831 0.348 . . . . 0.0 110.93 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.81 -33.64 68.71 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -66.67 -44.8 80.83 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.737 0.303 . . . . 0.0 110.76 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 87.0 mt -60.25 -52.6 59.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.797 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.47 -41.67 96.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.483 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.62 -35.59 92.06 Favored Glycine 0 C--O 1.225 -0.414 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.5 t80 -64.29 -43.94 93.2 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.1 0.476 . . . . 0.0 110.616 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 88.3 mt -65.9 -29.48 47.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.923 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.4 mm-40 -92.47 -50.68 5.5 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 112.403 0.52 . . . . 0.0 112.403 -177.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.34 28.97 9.09 Favored Glycine 0 N--CA 1.466 0.664 0 CA-C-N 116.387 -0.369 . . . . 0.0 112.405 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 42.89 -143.72 1.36 Allowed Glycine 0 CA--C 1.525 0.674 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.682 178.451 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.557 ' HE1' HD11 ' A' ' 18' ' ' ILE . 35.2 t-105 -51.15 -59.73 3.87 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 122.55 -0.382 . . . . 0.0 111.008 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 15.7 m -50.11 -34.04 20.68 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.86 -179.426 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.11 -37.76 63.77 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 37.7 ttp -57.23 -46.45 82.96 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.416 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.557 HD11 ' HE1' ' A' ' 14' ' ' TRP . 92.9 mt -64.1 -50.03 78.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.022 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -54.23 -41.4 68.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.704 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 1' ' ' GLY . . . -70.69 -33.81 66.84 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 74.1 t-105 -62.85 -49.7 73.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.768 0.318 . . . . 0.0 110.497 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 55.4 m-85 -80.88 -33.23 34.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.675 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.82 153.91 2.31 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 17.9 t . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.659 179.932 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 57.9 tp -66.06 -51.69 55.8 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 120.931 -0.308 . . . . 0.0 110.957 -179.405 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -63.17 -47.87 80.83 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.672 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.26 -34.39 67.37 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.3 -47.74 69.69 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 122.858 -0.201 . . . . 0.0 110.783 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 94.3 mt -59.55 -53.16 52.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.825 -179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.46 -41.46 93.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.907 0.384 . . . . 0.0 110.614 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.12 -35.19 91.74 Favored Glycine 0 C--O 1.227 -0.313 0 N-CA-C 110.437 -1.065 . . . . 0.0 110.437 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -65.45 -43.56 89.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.981 0.419 . . . . 0.0 110.526 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 86.2 mt -66.51 -26.92 38.72 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.886 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -92.67 -49.11 6.25 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -178.321 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.22 31.38 6.74 Favored Glycine 0 N--CA 1.464 0.526 0 C-N-CA 121.682 -0.294 . . . . 0.0 112.385 -178.52 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 42.19 -143.25 1.2 Allowed Glycine 0 CA--C 1.525 0.656 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.591 178.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.412 ' HE1' HD11 ' A' ' 18' ' ' ILE . 27.7 t-105 -51.18 -63.49 1.11 Allowed 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.778 -0.369 . . . . 0.0 111.445 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.4 m -47.38 -32.87 5.31 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.938 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.59 -37.36 68.22 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.404 ' C ' ' SD ' ' A' ' 17' ' ' MET . 13.7 tmm? -57.05 -47.27 81.36 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.71 0.29 . . . . 0.0 110.568 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.412 HD11 ' HE1' ' A' ' 14' ' ' TRP . 96.0 mt -62.17 -51.91 66.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.798 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -50.47 -47.05 57.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 -179.603 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.17 -34.53 86.39 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 71.4 t-105 -60.99 -53.28 59.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.748 0.309 . . . . 0.0 110.592 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -75.76 -32.33 59.92 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.553 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.02 -74.44 1.4 Allowed Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 12.1 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.913 -1.042 . . . . 0.0 110.591 179.857 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.171 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.3 tp -66.1 -51.63 56.22 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.735 0.302 . . . . 0.0 111.078 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -63.36 -44.88 93.55 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.693 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.13 -31.6 65.78 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.79 -46.94 64.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.621 0.248 . . . . 0.0 110.636 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 82.2 mt -60.76 -51.81 68.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.698 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.94 -42.21 85.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.902 0.382 . . . . 0.0 110.802 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.09 -33.62 87.73 Favored Glycine 0 C--O 1.227 -0.288 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -66.3 -43.89 85.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.168 0.509 . . . . 0.0 110.634 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 85.2 mt -66.95 -27.35 39.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.143 -179.276 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -92.65 -48.51 6.56 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -178.618 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.51 28.48 9.52 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 112.109 -0.396 . . . . 0.0 112.109 -178.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.78 -146.44 1.82 Allowed Glycine 0 CA--C 1.525 0.709 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.476 178.43 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.502 ' HE1' HD11 ' A' ' 18' ' ' ILE . 30.3 t-105 -50.73 -61.93 1.91 Allowed 'General case' 0 C--N 1.319 -0.758 0 O-C-N 122.481 -0.423 . . . . 0.0 111.192 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.2 m -48.42 -33.43 9.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.797 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.31 -37.55 70.87 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 40.4 ttp -57.21 -49.39 76.16 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.706 0.289 . . . . 0.0 110.638 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.502 HD11 ' HE1' ' A' ' 14' ' ' TRP . 92.0 mt -61.01 -50.26 81.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.063 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -53.01 -42.77 65.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.879 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.1 -34.99 77.09 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 76.0 t-105 -62.11 -48.42 80.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.632 0.254 . . . . 0.0 110.497 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 50.8 m-85 -78.06 -31.02 50.02 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.613 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 70.91 -2.39 17.96 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.756 -0.937 . . . . 0.0 110.756 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 90.2 p . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.644 -179.865 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 33.0 tp -62.75 -47.89 81.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.726 0.298 . . . . 0.0 111.065 -179.083 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -65.58 -47.32 76.16 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.861 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.33 -32.79 57.76 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.04 -45.72 66.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.758 0.313 . . . . 0.0 111.03 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 95.2 mt -59.58 -53.19 51.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.732 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.17 -42.44 93.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.868 0.366 . . . . 0.0 110.676 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.08 -34.37 89.75 Favored Glycine 0 C--O 1.225 -0.418 0 N-CA-C 110.186 -1.165 . . . . 0.0 110.186 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 37.3 t80 -64.71 -43.69 92.65 Favored 'General case' 0 C--O 1.221 -0.406 0 CA-C-O 121.147 0.498 . . . . 0.0 110.45 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 85.1 mt -68.11 -27.0 35.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.148 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -92.33 -48.29 6.75 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.7 28.98 8.49 Favored Glycine 0 N--CA 1.467 0.749 0 N-CA-C 112.118 -0.393 . . . . 0.0 112.118 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.2 -145.4 1.77 Allowed Glycine 0 CA--C 1.527 0.823 0 C-N-CA 120.562 -0.828 . . . . 0.0 111.453 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.549 ' HE1' HD11 ' A' ' 18' ' ' ILE . 29.9 t-105 -50.72 -60.32 3.17 Favored 'General case' 0 C--N 1.32 -0.701 0 O-C-N 122.467 -0.431 . . . . 0.0 111.307 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 90.4 m -50.07 -33.52 18.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.561 -0.291 . . . . 0.0 110.957 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 -36.46 71.01 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 46.4 ttp -58.52 -48.65 80.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.74 0.305 . . . . 0.0 110.709 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.549 HD11 ' HE1' ' A' ' 14' ' ' TRP . 89.9 mt -61.93 -50.36 80.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.954 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 2.3 m-20 -54.06 -44.31 70.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.704 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.37 -34.36 84.81 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 63.5 t-105 -62.68 -51.41 67.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.668 0.27 . . . . 0.0 110.591 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 53.8 m-85 -77.13 -34.36 56.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.694 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.43 36.74 62.87 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.8 m . . . . . 0 C--O 1.222 -0.392 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.494 -179.837 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.121 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.423 ' O ' HD13 ' A' ' 2' ' ' LEU . 0.2 OUTLIER -67.42 -56.05 11.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.876 0.37 . . . . 0.0 110.889 -179.293 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -63.1 -42.94 99.7 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.282 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.37 -33.26 65.44 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.51 -46.82 65.66 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.753 0.311 . . . . 0.0 110.478 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 75.9 mt -62.73 -51.19 75.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.841 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.45 -42.1 88.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.91 0.386 . . . . 0.0 110.475 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.26 -34.07 88.97 Favored Glycine 0 CA--C 1.52 0.383 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -65.26 -45.05 86.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.033 0.444 . . . . 0.0 110.505 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 92.5 mt -65.47 -28.66 44.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.246 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 24.3 mm-40 -91.31 -47.89 7.23 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -178.309 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.62 27.72 10.23 Favored Glycine 0 N--CA 1.469 0.871 0 N-CA-C 112.118 -0.393 . . . . 0.0 112.118 -178.204 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.84 -147.05 2.46 Favored Glycine 0 CA--C 1.524 0.628 0 C-N-CA 120.578 -0.82 . . . . 0.0 111.251 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.514 ' HE1' HD11 ' A' ' 18' ' ' ILE . 20.1 t-105 -50.61 -60.0 3.48 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.91 0.386 . . . . 0.0 111.321 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.3 m -50.66 -31.52 16.5 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.663 -179.589 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.78 -36.24 66.31 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' MET . . . . . 0.408 ' C ' ' SD ' ' A' ' 17' ' ' MET . 13.4 tmm? -59.21 -47.85 83.8 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.718 0.294 . . . . 0.0 110.834 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.514 HD11 ' HE1' ' A' ' 14' ' ' TRP . 90.2 mt -62.5 -50.36 80.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.889 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -54.5 -41.68 69.9 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.727 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.08 -33.6 74.54 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -61.79 -48.31 81.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.799 0.333 . . . . 0.0 110.578 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -70.85 -30.91 67.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.629 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.73 126.03 0.12 Allowed Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 86.7 p . . . . . 0 C--O 1.219 -0.519 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.55 -179.872 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 59.4 tp -64.26 -50.73 66.81 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-O 120.862 0.363 . . . . 0.0 110.895 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -64.56 -46.95 80.57 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.769 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.14 -33.47 61.12 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -68.49 -46.13 70.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.707 0.289 . . . . 0.0 110.757 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.5 mt -61.87 -51.8 68.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.837 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.31 -42.68 92.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.962 0.41 . . . . 0.0 110.619 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.64 -36.3 93.06 Favored Glycine 0 C--O 1.225 -0.411 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 40.2 t80 -62.72 -44.11 97.07 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.076 0.465 . . . . 0.0 110.746 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 87.8 mt -67.62 -27.78 39.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.927 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -89.61 -50.06 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -178.055 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.78 31.98 6.06 Favored Glycine 0 N--CA 1.464 0.539 0 N-CA-C 112.27 -0.332 . . . . 0.0 112.27 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.23 -145.23 1.83 Allowed Glycine 0 CA--C 1.525 0.687 0 C-N-CA 120.618 -0.801 . . . . 0.0 111.628 178.49 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 30.8 t-105 -50.09 -62.45 1.57 Allowed 'General case' 0 C--N 1.32 -0.678 0 O-C-N 122.605 -0.35 . . . . 0.0 111.296 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.4 m -49.73 -35.34 21.76 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.849 0.357 . . . . 0.0 110.956 -179.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.54 -37.73 93.98 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.709 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 36.5 ttp -61.27 -40.94 95.95 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.494 179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.5 mm -61.7 -48.62 87.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.981 -179.487 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -60.72 -42.61 97.61 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.734 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.03 -37.2 94.56 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 73.9 t-105 -62.13 -45.85 91.62 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.725 0.298 . . . . 0.0 110.507 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -74.34 -34.21 63.35 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.715 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.93 1.1 46.27 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.4 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.97 -1.015 . . . . 0.0 110.613 -179.847 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.7 tp -65.22 -49.55 69.26 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.712 0.292 . . . . 0.0 111.121 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -63.64 -47.85 79.63 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.634 -179.36 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.92 -32.52 66.5 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.18 -46.38 74.13 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.619 0.247 . . . . 0.0 110.657 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.52 -50.84 78.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.718 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.82 -42.45 85.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.625 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.92 -34.14 89.13 Favored Glycine 0 C--O 1.225 -0.459 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.0 t80 -65.35 -44.45 87.66 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.079 0.466 . . . . 0.0 110.558 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 89.4 mt -67.07 -27.33 39.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.064 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -91.69 -48.46 6.81 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -178.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 16' ' ' GLY . . . -112.89 30.26 7.55 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 111.998 -0.441 . . . . 0.0 111.998 -178.57 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.11 -146.23 1.52 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.478 178.505 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' TRP . . . . . 0.534 ' HE1' HD11 ' A' ' 18' ' ' ILE . 28.8 t-105 -50.59 -61.82 1.96 Allowed 'General case' 0 C--N 1.32 -0.717 0 O-C-N 122.488 -0.419 . . . . 0.0 111.364 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.0 m -49.11 -32.35 9.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.775 -179.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 12' ' ' GLY . . . -70.73 -36.14 66.72 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 46.5 ttp -58.85 -45.35 90.29 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.756 0.312 . . . . 0.0 110.567 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.534 HD11 ' HE1' ' A' ' 14' ' ' TRP . 79.8 mt -63.9 -50.91 75.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.005 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -52.77 -41.98 64.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.721 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.43 -34.48 74.2 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 68.8 t-105 -63.34 -48.76 76.64 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.687 0.28 . . . . 0.0 110.535 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -74.2 -31.12 62.52 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.629 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.43 -66.01 1.31 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 12.4 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.037 -0.982 . . . . 0.0 110.586 179.967 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 22.5 tp . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.808 0.337 . . . . 0.0 111.036 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -65.22 -48.33 73.71 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.733 -179.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.2 -32.34 63.28 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -68.35 -44.99 74.04 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.724 0.297 . . . . 0.0 110.666 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 95.3 mt -61.67 -51.09 76.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.574 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.73 -42.78 85.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.954 0.407 . . . . 0.0 110.819 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.41 -34.46 90.0 Favored Glycine 0 C--O 1.226 -0.354 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -65.39 -44.31 87.92 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.034 0.445 . . . . 0.0 110.574 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 91.3 mt -65.05 -28.68 45.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.183 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -92.18 -47.23 7.34 Favored 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 112.577 0.584 . . . . 0.0 112.577 -178.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.87 27.98 9.82 Favored Glycine 0 N--CA 1.47 0.956 0 N-CA-C 111.981 -0.448 . . . . 0.0 111.981 -178.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.85 -146.49 1.85 Allowed Glycine 0 CA--C 1.526 0.721 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.454 178.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.444 ' HE1' HD11 ' A' ' 18' ' ' ILE . 24.7 t-105 -49.66 -61.88 1.87 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.89 0.376 . . . . 0.0 111.381 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 19.0 m -49.56 -32.24 12.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.869 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.48 -37.44 78.69 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 53.3 ttp -58.27 -46.49 85.93 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.748 0.308 . . . . 0.0 110.697 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.444 HD11 ' HE1' ' A' ' 14' ' ' TRP . 84.4 mt -62.58 -49.08 85.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.826 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -55.52 -45.61 77.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.758 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.74 -34.76 89.73 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 75.4 t-105 -62.91 -47.98 80.92 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.705 0.288 . . . . 0.0 110.584 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 . . . . . 0 C--N 1.331 -0.222 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.661 -179.804 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.2 tp . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.797 0.332 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -65.31 -45.52 84.04 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.435 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.38 -32.54 57.73 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.13 -46.76 60.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.721 0.296 . . . . 0.0 110.469 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 91.2 mt -60.4 -52.71 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.659 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.416 ' O ' ' OE2' ' A' ' 11' ' ' GLU . . . -66.37 -42.46 87.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.924 0.392 . . . . 0.0 110.543 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.89 -34.7 90.63 Favored Glycine 0 C--O 1.227 -0.288 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 26.9 t80 -64.16 -45.62 87.63 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.946 0.403 . . . . 0.0 110.74 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 73.8 mt -67.22 -27.39 38.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.243 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.493 ' N ' ' OE1' ' A' ' 11' ' ' GLU . 0.3 OUTLIER -89.43 -46.82 8.43 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -178.314 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.87 29.17 7.62 Favored Glycine 0 N--CA 1.471 0.968 0 N-CA-C 111.913 -0.475 . . . . 0.0 111.913 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.4 -146.12 2.41 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 120.391 -0.909 . . . . 0.0 111.438 179.068 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.481 ' HE1' HD11 ' A' ' 18' ' ' ILE . 34.7 t-105 -50.39 -61.27 2.28 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.766 0.317 . . . . 0.0 111.179 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.8 m -49.34 -33.62 13.87 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.879 0.371 . . . . 0.0 110.843 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.39 -37.22 79.35 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 42.4 ttp -58.15 -47.01 84.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.759 0.314 . . . . 0.0 110.625 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.481 HD11 ' HE1' ' A' ' 14' ' ' TRP . 83.6 mt -62.04 -50.3 80.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.879 -179.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -53.33 -43.27 67.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.811 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.38 -33.96 68.43 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.159 -0.777 . . . . 0.0 111.159 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 70.2 t-105 -66.23 -43.86 85.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.623 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 15.7 m-85 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.243 -179.883 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.5 tp . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.702 0.287 . . . . 0.0 110.487 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -64.5 -46.94 80.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.585 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.08 -32.0 62.39 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.854 -0.899 . . . . 0.0 110.854 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.34 -47.87 63.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.742 0.306 . . . . 0.0 110.693 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 75.4 mt -61.28 -52.06 65.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.929 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.32 -41.55 93.86 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.006 0.431 . . . . 0.0 110.583 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.52 -35.34 91.91 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.2 t80 -64.43 -44.69 90.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.039 0.447 . . . . 0.0 110.508 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 89.9 mt -64.26 -29.39 47.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.25 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mm-40 -92.22 -46.54 7.68 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -178.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.16 28.16 9.49 Favored Glycine 0 N--CA 1.469 0.848 0 N-CA-C 112.248 -0.341 . . . . 0.0 112.248 -178.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.32 -146.05 1.68 Allowed Glycine 0 CA--C 1.523 0.539 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.35 179.083 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.525 ' HE1' HD11 ' A' ' 18' ' ' ILE . 26.3 t-105 -50.13 -60.71 2.69 Favored 'General case' 0 C--N 1.323 -0.585 0 O-C-N 122.514 -0.404 . . . . 0.0 111.249 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.4 m -49.0 -31.68 7.9 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.011 0.434 . . . . 0.0 110.825 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.27 -37.37 71.17 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . 0.418 ' C ' ' SD ' ' A' ' 17' ' ' MET . 12.8 tmm? -58.19 -48.44 80.3 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.692 0.282 . . . . 0.0 110.887 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.525 HD11 ' HE1' ' A' ' 14' ' ' TRP . 86.1 mt -62.04 -53.22 50.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.265 -179.718 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -51.13 -44.81 61.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.907 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.2 -32.74 72.72 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 67.0 t-105 -63.81 -50.46 68.85 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.765 0.317 . . . . 0.0 110.692 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.352 179.988 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.1 tp . . . . . 0 N--CA 1.452 -0.362 0 CA-C-O 120.848 0.356 . . . . 0.0 111.038 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -63.68 -45.97 87.64 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.831 0.348 . . . . 0.0 110.93 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.81 -33.64 68.71 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -66.67 -44.8 80.83 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.737 0.303 . . . . 0.0 110.76 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 87.0 mt -60.25 -52.6 59.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.797 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.47 -41.67 96.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.483 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.62 -35.59 92.06 Favored Glycine 0 C--O 1.225 -0.414 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.5 t80 -64.29 -43.94 93.2 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.1 0.476 . . . . 0.0 110.616 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 88.3 mt -65.9 -29.48 47.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.923 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.4 mm-40 -92.47 -50.68 5.5 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 112.403 0.52 . . . . 0.0 112.403 -177.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.34 28.97 9.09 Favored Glycine 0 N--CA 1.466 0.664 0 CA-C-N 116.387 -0.369 . . . . 0.0 112.405 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 42.89 -143.72 1.36 Allowed Glycine 0 CA--C 1.525 0.674 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.682 178.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.557 ' HE1' HD11 ' A' ' 18' ' ' ILE . 35.2 t-105 -51.15 -59.73 3.87 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 122.55 -0.382 . . . . 0.0 111.008 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 15.7 m -50.11 -34.04 20.68 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.86 -179.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.11 -37.76 63.77 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 37.7 ttp -57.23 -46.45 82.96 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.416 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.557 HD11 ' HE1' ' A' ' 14' ' ' TRP . 92.9 mt -64.1 -50.03 78.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.022 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -54.23 -41.4 68.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.704 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.69 -33.81 66.84 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 74.1 t-105 -62.85 -49.7 73.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.768 0.318 . . . . 0.0 110.497 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 55.4 m-85 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.675 -179.511 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 57.9 tp . . . . . 0 N--CA 1.453 -0.3 0 CA-C-O 120.701 0.286 . . . . 0.0 110.957 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -63.17 -47.87 80.83 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.672 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.26 -34.39 67.37 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.3 -47.74 69.69 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 122.858 -0.201 . . . . 0.0 110.783 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 94.3 mt -59.55 -53.16 52.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.825 -179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.46 -41.46 93.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.907 0.384 . . . . 0.0 110.614 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.12 -35.19 91.74 Favored Glycine 0 C--O 1.227 -0.313 0 N-CA-C 110.437 -1.065 . . . . 0.0 110.437 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -65.45 -43.56 89.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.981 0.419 . . . . 0.0 110.526 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 86.2 mt -66.51 -26.92 38.72 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.886 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -92.67 -49.11 6.25 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -178.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.22 31.38 6.74 Favored Glycine 0 N--CA 1.464 0.526 0 C-N-CA 121.682 -0.294 . . . . 0.0 112.385 -178.52 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 42.19 -143.25 1.2 Allowed Glycine 0 CA--C 1.525 0.656 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.591 178.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.412 ' HE1' HD11 ' A' ' 18' ' ' ILE . 27.7 t-105 -51.18 -63.49 1.11 Allowed 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.778 -0.369 . . . . 0.0 111.445 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.4 m -47.38 -32.87 5.31 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.938 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.59 -37.36 68.22 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . 0.404 ' C ' ' SD ' ' A' ' 17' ' ' MET . 13.7 tmm? -57.05 -47.27 81.36 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.71 0.29 . . . . 0.0 110.568 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.412 HD11 ' HE1' ' A' ' 14' ' ' TRP . 96.0 mt -62.17 -51.91 66.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.798 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -50.47 -47.05 57.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 -179.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.17 -34.53 86.39 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 71.4 t-105 -60.99 -53.28 59.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.748 0.309 . . . . 0.0 110.592 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 . . . . . 0 C--N 1.327 -0.413 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.553 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.3 tp . . . . . 0 N--CA 1.454 -0.249 0 CA-C-O 120.735 0.302 . . . . 0.0 111.078 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -63.36 -44.88 93.55 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.693 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.13 -31.6 65.78 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.79 -46.94 64.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.621 0.248 . . . . 0.0 110.636 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 82.2 mt -60.76 -51.81 68.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.698 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.94 -42.21 85.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.902 0.382 . . . . 0.0 110.802 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.09 -33.62 87.73 Favored Glycine 0 C--O 1.227 -0.288 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -66.3 -43.89 85.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.168 0.509 . . . . 0.0 110.634 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 85.2 mt -66.95 -27.35 39.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.143 -179.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -92.65 -48.51 6.56 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -178.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.51 28.48 9.52 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 112.109 -0.396 . . . . 0.0 112.109 -178.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.78 -146.44 1.82 Allowed Glycine 0 CA--C 1.525 0.709 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.476 178.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.502 ' HE1' HD11 ' A' ' 18' ' ' ILE . 30.3 t-105 -50.73 -61.93 1.91 Allowed 'General case' 0 C--N 1.319 -0.758 0 O-C-N 122.481 -0.423 . . . . 0.0 111.192 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.2 m -48.42 -33.43 9.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.797 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.31 -37.55 70.87 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 40.4 ttp -57.21 -49.39 76.16 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.706 0.289 . . . . 0.0 110.638 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.502 HD11 ' HE1' ' A' ' 14' ' ' TRP . 92.0 mt -61.01 -50.26 81.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.063 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -53.01 -42.77 65.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.879 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.1 -34.99 77.09 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 76.0 t-105 -62.11 -48.42 80.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.632 0.254 . . . . 0.0 110.497 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 50.8 m-85 . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.613 -179.888 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 33.0 tp . . . . . 0 N--CA 1.455 -0.176 0 CA-C-O 120.726 0.298 . . . . 0.0 111.065 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -65.58 -47.32 76.16 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.861 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.33 -32.79 57.76 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.04 -45.72 66.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.758 0.313 . . . . 0.0 111.03 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 95.2 mt -59.58 -53.19 51.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.732 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.17 -42.44 93.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.868 0.366 . . . . 0.0 110.676 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.08 -34.37 89.75 Favored Glycine 0 C--O 1.225 -0.418 0 N-CA-C 110.186 -1.165 . . . . 0.0 110.186 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 37.3 t80 -64.71 -43.69 92.65 Favored 'General case' 0 C--O 1.221 -0.406 0 CA-C-O 121.147 0.498 . . . . 0.0 110.45 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 85.1 mt -68.11 -27.0 35.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.148 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -92.33 -48.29 6.75 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.7 28.98 8.49 Favored Glycine 0 N--CA 1.467 0.749 0 N-CA-C 112.118 -0.393 . . . . 0.0 112.118 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.2 -145.4 1.77 Allowed Glycine 0 CA--C 1.527 0.823 0 C-N-CA 120.562 -0.828 . . . . 0.0 111.453 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.549 ' HE1' HD11 ' A' ' 18' ' ' ILE . 29.9 t-105 -50.72 -60.32 3.17 Favored 'General case' 0 C--N 1.32 -0.701 0 O-C-N 122.467 -0.431 . . . . 0.0 111.307 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 90.4 m -50.07 -33.52 18.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.561 -0.291 . . . . 0.0 110.957 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 -36.46 71.01 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 46.4 ttp -58.52 -48.65 80.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.74 0.305 . . . . 0.0 110.709 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.549 HD11 ' HE1' ' A' ' 14' ' ' TRP . 89.9 mt -61.93 -50.36 80.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.954 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 2.3 m-20 -54.06 -44.31 70.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.704 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.37 -34.36 84.81 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 63.5 t-105 -62.68 -51.41 67.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.668 0.27 . . . . 0.0 110.591 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 53.8 m-85 . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.694 -179.89 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.423 ' O ' HD13 ' A' ' 2' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.527 0.088 0 CA-C-O 120.876 0.37 . . . . 0.0 110.889 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -63.1 -42.94 99.7 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.282 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.37 -33.26 65.44 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.51 -46.82 65.66 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.753 0.311 . . . . 0.0 110.478 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 75.9 mt -62.73 -51.19 75.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.841 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.45 -42.1 88.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.91 0.386 . . . . 0.0 110.475 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.26 -34.07 88.97 Favored Glycine 0 CA--C 1.52 0.383 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -65.26 -45.05 86.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.033 0.444 . . . . 0.0 110.505 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 92.5 mt -65.47 -28.66 44.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.246 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 24.3 mm-40 -91.31 -47.89 7.23 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -178.309 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.62 27.72 10.23 Favored Glycine 0 N--CA 1.469 0.871 0 N-CA-C 112.118 -0.393 . . . . 0.0 112.118 -178.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.84 -147.05 2.46 Favored Glycine 0 CA--C 1.524 0.628 0 C-N-CA 120.578 -0.82 . . . . 0.0 111.251 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.514 ' HE1' HD11 ' A' ' 18' ' ' ILE . 20.1 t-105 -50.61 -60.0 3.48 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.91 0.386 . . . . 0.0 111.321 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.3 m -50.66 -31.52 16.5 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.663 -179.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.78 -36.24 66.31 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . 0.408 ' C ' ' SD ' ' A' ' 17' ' ' MET . 13.4 tmm? -59.21 -47.85 83.8 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.718 0.294 . . . . 0.0 110.834 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.514 HD11 ' HE1' ' A' ' 14' ' ' TRP . 90.2 mt -62.5 -50.36 80.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.889 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -54.5 -41.68 69.9 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.727 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.08 -33.6 74.54 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -61.79 -48.31 81.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.799 0.333 . . . . 0.0 110.578 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.629 -179.902 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 59.4 tp . . . . . 0 N--CA 1.451 -0.375 0 CA-C-O 120.862 0.363 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -64.56 -46.95 80.57 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.769 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.14 -33.47 61.12 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -68.49 -46.13 70.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.707 0.289 . . . . 0.0 110.757 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.5 mt -61.87 -51.8 68.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.837 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.31 -42.68 92.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.962 0.41 . . . . 0.0 110.619 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.64 -36.3 93.06 Favored Glycine 0 C--O 1.225 -0.411 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 40.2 t80 -62.72 -44.11 97.07 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.076 0.465 . . . . 0.0 110.746 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 87.8 mt -67.62 -27.78 39.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.927 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -89.61 -50.06 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -178.055 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.78 31.98 6.06 Favored Glycine 0 N--CA 1.464 0.539 0 N-CA-C 112.27 -0.332 . . . . 0.0 112.27 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.23 -145.23 1.83 Allowed Glycine 0 CA--C 1.525 0.687 0 C-N-CA 120.618 -0.801 . . . . 0.0 111.628 178.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 30.8 t-105 -50.09 -62.45 1.57 Allowed 'General case' 0 C--N 1.32 -0.678 0 O-C-N 122.605 -0.35 . . . . 0.0 111.296 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.4 m -49.73 -35.34 21.76 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.849 0.357 . . . . 0.0 110.956 -179.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.54 -37.73 93.98 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 36.5 ttp -61.27 -40.94 95.95 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.494 179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.5 mm -61.7 -48.62 87.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.981 -179.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -60.72 -42.61 97.61 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.734 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.03 -37.2 94.56 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 73.9 t-105 -62.13 -45.85 91.62 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.725 0.298 . . . . 0.0 110.507 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 . . . . . 0 C--N 1.327 -0.382 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.715 -179.629 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.7 tp . . . . . 0 N--CA 1.451 -0.425 0 CA-C-O 120.712 0.292 . . . . 0.0 111.121 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -63.64 -47.85 79.63 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.634 -179.36 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.92 -32.52 66.5 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.18 -46.38 74.13 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.619 0.247 . . . . 0.0 110.657 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.52 -50.84 78.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.718 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.82 -42.45 85.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.625 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.92 -34.14 89.13 Favored Glycine 0 C--O 1.225 -0.459 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.0 t80 -65.35 -44.45 87.66 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.079 0.466 . . . . 0.0 110.558 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 89.4 mt -67.07 -27.33 39.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.064 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -91.69 -48.46 6.81 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -178.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 16' ' ' GLY . . . -112.89 30.26 7.55 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 111.998 -0.441 . . . . 0.0 111.998 -178.57 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.11 -146.23 1.52 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.478 178.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' TRP . . . . . 0.534 ' HE1' HD11 ' A' ' 18' ' ' ILE . 28.8 t-105 -50.59 -61.82 1.96 Allowed 'General case' 0 C--N 1.32 -0.717 0 O-C-N 122.488 -0.419 . . . . 0.0 111.364 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.0 m -49.11 -32.35 9.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.775 -179.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 12' ' ' GLY . . . -70.73 -36.14 66.72 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 46.5 ttp -58.85 -45.35 90.29 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.756 0.312 . . . . 0.0 110.567 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.534 HD11 ' HE1' ' A' ' 14' ' ' TRP . 79.8 mt -63.9 -50.91 75.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.005 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -52.77 -41.98 64.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.721 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.43 -34.48 74.2 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 68.8 t-105 -63.34 -48.76 76.64 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.687 0.28 . . . . 0.0 110.535 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.629 -179.549 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 22.5 tp -61.04 -45.58 94.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.808 0.337 . . . . 0.0 111.036 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -65.22 -48.33 73.71 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.733 -179.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.2 -32.34 63.28 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -68.35 -44.99 74.04 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.724 0.297 . . . . 0.0 110.666 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 95.3 mt -61.67 -51.09 76.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.574 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.73 -42.78 85.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.954 0.407 . . . . 0.0 110.819 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.41 -34.46 90.0 Favored Glycine 0 C--O 1.226 -0.354 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -65.39 -44.31 87.92 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.034 0.445 . . . . 0.0 110.574 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 91.3 mt -65.05 -28.68 45.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.183 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -92.18 -47.23 7.34 Favored 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 112.577 0.584 . . . . 0.0 112.577 -178.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.87 27.98 9.82 Favored Glycine 0 N--CA 1.47 0.956 0 N-CA-C 111.981 -0.448 . . . . 0.0 111.981 -178.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.85 -146.49 1.85 Allowed Glycine 0 CA--C 1.526 0.721 0 C-N-CA 120.497 -0.859 . . . . 0.0 111.454 178.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.444 ' HE1' HD11 ' A' ' 18' ' ' ILE . 24.7 t-105 -49.66 -61.88 1.87 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.89 0.376 . . . . 0.0 111.381 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 19.0 m -49.56 -32.24 12.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.869 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.48 -37.44 78.69 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 53.3 ttp -58.27 -46.49 85.93 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.748 0.308 . . . . 0.0 110.697 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.444 HD11 ' HE1' ' A' ' 14' ' ' TRP . 84.4 mt -62.58 -49.08 85.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.826 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -55.52 -45.61 77.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.758 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.74 -34.76 89.73 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 75.4 t-105 -62.91 -47.98 80.92 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.705 0.288 . . . . 0.0 110.584 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 -77.57 -33.04 54.1 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.661 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.29 -87.88 0.7 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 50.1 m . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 118.079 -0.962 . . . . 0.0 110.621 -179.996 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.296 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.2 tp -64.57 -52.21 58.78 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.797 0.332 . . . . 0.0 110.613 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -65.31 -45.52 84.04 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.435 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.38 -32.54 57.73 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.13 -46.76 60.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.721 0.296 . . . . 0.0 110.469 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 91.2 mt -60.4 -52.71 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.659 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.416 ' O ' ' OE2' ' A' ' 11' ' ' GLU . . . -66.37 -42.46 87.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.924 0.392 . . . . 0.0 110.543 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.89 -34.7 90.63 Favored Glycine 0 C--O 1.227 -0.288 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 26.9 t80 -64.16 -45.62 87.63 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.946 0.403 . . . . 0.0 110.74 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 73.8 mt -67.22 -27.39 38.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.243 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.493 ' N ' ' OE1' ' A' ' 11' ' ' GLU . 0.3 OUTLIER -89.43 -46.82 8.43 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -178.314 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.87 29.17 7.62 Favored Glycine 0 N--CA 1.471 0.968 0 N-CA-C 111.913 -0.475 . . . . 0.0 111.913 -178.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.4 -146.12 2.41 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 120.391 -0.909 . . . . 0.0 111.438 179.068 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.481 ' HE1' HD11 ' A' ' 18' ' ' ILE . 34.7 t-105 -50.39 -61.27 2.28 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.766 0.317 . . . . 0.0 111.179 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.8 m -49.34 -33.62 13.87 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.879 0.371 . . . . 0.0 110.843 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.39 -37.22 79.35 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 42.4 ttp -58.15 -47.01 84.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.759 0.314 . . . . 0.0 110.625 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.481 HD11 ' HE1' ' A' ' 14' ' ' TRP . 83.6 mt -62.04 -50.3 80.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.879 -179.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -53.33 -43.27 67.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.811 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.38 -33.96 68.43 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.159 -0.777 . . . . 0.0 111.159 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 70.2 t-105 -66.23 -43.86 85.41 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.623 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . 0.508 ' O ' ' N ' ' A' ' 24' ' ' SER . 15.7 m-85 -73.65 -24.57 60.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.243 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -59.23 78.45 0.01 OUTLIER Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.508 ' N ' ' O ' ' A' ' 22' ' ' TYR . 31.6 t . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 117.877 -1.059 . . . . 0.0 110.527 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.187 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.5 tp -67.79 -49.88 60.01 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.954 -0.298 . . . . 0.0 110.487 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -64.5 -46.94 80.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.585 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.08 -32.0 62.39 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.854 -0.899 . . . . 0.0 110.854 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.34 -47.87 63.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.742 0.306 . . . . 0.0 110.693 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 75.4 mt -61.28 -52.06 65.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.929 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.32 -41.55 93.86 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.006 0.431 . . . . 0.0 110.583 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.52 -35.34 91.91 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.2 t80 -64.43 -44.69 90.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.039 0.447 . . . . 0.0 110.508 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 89.9 mt -64.26 -29.39 47.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.25 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mm-40 -92.22 -46.54 7.68 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -178.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.16 28.16 9.49 Favored Glycine 0 N--CA 1.469 0.848 0 N-CA-C 112.248 -0.341 . . . . 0.0 112.248 -178.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.32 -146.05 1.68 Allowed Glycine 0 CA--C 1.523 0.539 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.35 179.083 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.525 ' HE1' HD11 ' A' ' 18' ' ' ILE . 26.3 t-105 -50.13 -60.71 2.69 Favored 'General case' 0 C--N 1.323 -0.585 0 O-C-N 122.514 -0.404 . . . . 0.0 111.249 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.4 m -49.0 -31.68 7.9 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.011 0.434 . . . . 0.0 110.825 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.27 -37.37 71.17 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.418 ' C ' ' SD ' ' A' ' 17' ' ' MET . 12.8 tmm? -58.19 -48.44 80.3 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.692 0.282 . . . . 0.0 110.887 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.525 HD11 ' HE1' ' A' ' 14' ' ' TRP . 86.1 mt -62.04 -53.22 50.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.265 -179.718 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 64.0 m-20 -51.13 -44.81 61.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.907 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.2 -32.74 72.72 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 67.0 t-105 -63.81 -50.46 68.85 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.765 0.317 . . . . 0.0 110.692 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -75.23 -28.06 59.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.352 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -53.24 135.54 40.29 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.736 -0.945 . . . . 0.0 110.736 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 32.0 p . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.456 179.871 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 18.1 tp -60.76 -50.96 71.37 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 120.848 0.356 . . . . 0.0 111.038 -179.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -63.68 -45.97 87.64 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.831 0.348 . . . . 0.0 110.93 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.81 -33.64 68.71 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -66.67 -44.8 80.83 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.737 0.303 . . . . 0.0 110.76 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 87.0 mt -60.25 -52.6 59.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.797 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -64.47 -41.67 96.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.483 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.62 -35.59 92.06 Favored Glycine 0 C--O 1.225 -0.414 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 56.5 t80 -64.29 -43.94 93.2 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.1 0.476 . . . . 0.0 110.616 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 88.3 mt -65.9 -29.48 47.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.923 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.4 mm-40 -92.47 -50.68 5.5 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 112.403 0.52 . . . . 0.0 112.403 -177.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.34 28.97 9.09 Favored Glycine 0 N--CA 1.466 0.664 0 CA-C-N 116.387 -0.369 . . . . 0.0 112.405 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 42.89 -143.72 1.36 Allowed Glycine 0 CA--C 1.525 0.674 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.682 178.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.557 ' HE1' HD11 ' A' ' 18' ' ' ILE . 35.2 t-105 -51.15 -59.73 3.87 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 122.55 -0.382 . . . . 0.0 111.008 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 15.7 m -50.11 -34.04 20.68 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.86 -179.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -71.11 -37.76 63.77 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 37.7 ttp -57.23 -46.45 82.96 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.416 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.557 HD11 ' HE1' ' A' ' 14' ' ' TRP . 92.9 mt -64.1 -50.03 78.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.022 -179.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -54.23 -41.4 68.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.704 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 1' ' ' GLY . . . -70.69 -33.81 66.84 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 74.1 t-105 -62.85 -49.7 73.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.768 0.318 . . . . 0.0 110.497 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 55.4 m-85 -80.88 -33.23 34.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.675 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.82 153.91 2.31 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 17.9 t . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.659 179.932 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 57.9 tp -66.06 -51.69 55.8 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 120.931 -0.308 . . . . 0.0 110.957 -179.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -63.17 -47.87 80.83 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.672 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.26 -34.39 67.37 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.3 -47.74 69.69 Favored 'General case' 0 C--N 1.328 -0.336 0 O-C-N 122.858 -0.201 . . . . 0.0 110.783 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 94.3 mt -59.55 -53.16 52.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.825 -179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.46 -41.46 93.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.907 0.384 . . . . 0.0 110.614 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.12 -35.19 91.74 Favored Glycine 0 C--O 1.227 -0.313 0 N-CA-C 110.437 -1.065 . . . . 0.0 110.437 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -65.45 -43.56 89.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.981 0.419 . . . . 0.0 110.526 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 86.2 mt -66.51 -26.92 38.72 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.886 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -92.67 -49.11 6.25 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -178.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.22 31.38 6.74 Favored Glycine 0 N--CA 1.464 0.526 0 C-N-CA 121.682 -0.294 . . . . 0.0 112.385 -178.52 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 42.19 -143.25 1.2 Allowed Glycine 0 CA--C 1.525 0.656 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.591 178.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.412 ' HE1' HD11 ' A' ' 18' ' ' ILE . 27.7 t-105 -51.18 -63.49 1.11 Allowed 'General case' 0 C--N 1.32 -0.687 0 C-N-CA 120.778 -0.369 . . . . 0.0 111.445 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 8.4 m -47.38 -32.87 5.31 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.938 -179.491 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.59 -37.36 68.22 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.404 ' C ' ' SD ' ' A' ' 17' ' ' MET . 13.7 tmm? -57.05 -47.27 81.36 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.71 0.29 . . . . 0.0 110.568 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.412 HD11 ' HE1' ' A' ' 14' ' ' TRP . 96.0 mt -62.17 -51.91 66.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.798 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -50.47 -47.05 57.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.829 -179.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.17 -34.53 86.39 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 71.4 t-105 -60.99 -53.28 59.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.748 0.309 . . . . 0.0 110.592 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -75.76 -32.33 59.92 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.553 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 75.02 -74.44 1.4 Allowed Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 12.1 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.913 -1.042 . . . . 0.0 110.591 179.857 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.171 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.3 tp -66.1 -51.63 56.22 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.735 0.302 . . . . 0.0 111.078 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -63.36 -44.88 93.55 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.693 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -58.13 -31.6 65.78 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.79 -46.94 64.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.621 0.248 . . . . 0.0 110.636 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 82.2 mt -60.76 -51.81 68.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.698 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.94 -42.21 85.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.902 0.382 . . . . 0.0 110.802 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.09 -33.62 87.73 Favored Glycine 0 C--O 1.227 -0.288 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -66.3 -43.89 85.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.168 0.509 . . . . 0.0 110.634 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 85.2 mt -66.95 -27.35 39.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.143 -179.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 60.4 mm-40 -92.65 -48.51 6.56 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -178.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.51 28.48 9.52 Favored Glycine 0 N--CA 1.467 0.75 0 N-CA-C 112.109 -0.396 . . . . 0.0 112.109 -178.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.78 -146.44 1.82 Allowed Glycine 0 CA--C 1.525 0.709 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.476 178.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.502 ' HE1' HD11 ' A' ' 18' ' ' ILE . 30.3 t-105 -50.73 -61.93 1.91 Allowed 'General case' 0 C--N 1.319 -0.758 0 O-C-N 122.481 -0.423 . . . . 0.0 111.192 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.2 m -48.42 -33.43 9.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.797 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.31 -37.55 70.87 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 40.4 ttp -57.21 -49.39 76.16 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.706 0.289 . . . . 0.0 110.638 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.502 HD11 ' HE1' ' A' ' 14' ' ' TRP . 92.0 mt -61.01 -50.26 81.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.063 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -53.01 -42.77 65.97 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.879 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.1 -34.99 77.09 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 76.0 t-105 -62.11 -48.42 80.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.632 0.254 . . . . 0.0 110.497 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 50.8 m-85 -78.06 -31.02 50.02 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.613 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 70.91 -2.39 17.96 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 110.756 -0.937 . . . . 0.0 110.756 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 90.2 p . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.644 -179.865 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 33.0 tp -62.75 -47.89 81.56 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.726 0.298 . . . . 0.0 111.065 -179.083 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -65.58 -47.32 76.16 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.861 -179.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.33 -32.79 57.76 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -70.04 -45.72 66.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.758 0.313 . . . . 0.0 111.03 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 95.2 mt -59.58 -53.19 51.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.732 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.17 -42.44 93.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.868 0.366 . . . . 0.0 110.676 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.08 -34.37 89.75 Favored Glycine 0 C--O 1.225 -0.418 0 N-CA-C 110.186 -1.165 . . . . 0.0 110.186 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 37.3 t80 -64.71 -43.69 92.65 Favored 'General case' 0 C--O 1.221 -0.406 0 CA-C-O 121.147 0.498 . . . . 0.0 110.45 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 85.1 mt -68.11 -27.0 35.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.148 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.6 mm-40 -92.33 -48.29 6.75 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.395 0.517 . . . . 0.0 112.395 -178.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -112.7 28.98 8.49 Favored Glycine 0 N--CA 1.467 0.749 0 N-CA-C 112.118 -0.393 . . . . 0.0 112.118 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.2 -145.4 1.77 Allowed Glycine 0 CA--C 1.527 0.823 0 C-N-CA 120.562 -0.828 . . . . 0.0 111.453 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.549 ' HE1' HD11 ' A' ' 18' ' ' ILE . 29.9 t-105 -50.72 -60.32 3.17 Favored 'General case' 0 C--N 1.32 -0.701 0 O-C-N 122.467 -0.431 . . . . 0.0 111.307 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 90.4 m -50.07 -33.52 18.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.561 -0.291 . . . . 0.0 110.957 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 -36.46 71.01 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 46.4 ttp -58.52 -48.65 80.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.74 0.305 . . . . 0.0 110.709 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.549 HD11 ' HE1' ' A' ' 14' ' ' TRP . 89.9 mt -61.93 -50.36 80.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.954 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 19' ' ' ASP . 2.3 m-20 -54.06 -44.31 70.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.704 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.37 -34.36 84.81 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 63.5 t-105 -62.68 -51.41 67.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.668 0.27 . . . . 0.0 110.591 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 53.8 m-85 -77.13 -34.36 56.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.694 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.43 36.74 62.87 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.8 m . . . . . 0 C--O 1.222 -0.392 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.494 -179.837 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.121 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.423 ' O ' HD13 ' A' ' 2' ' ' LEU . 0.2 OUTLIER -67.42 -56.05 11.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.876 0.37 . . . . 0.0 110.889 -179.293 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -63.1 -42.94 99.7 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.282 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.37 -33.26 65.44 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -69.51 -46.82 65.66 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.753 0.311 . . . . 0.0 110.478 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 75.9 mt -62.73 -51.19 75.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.841 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.45 -42.1 88.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.91 0.386 . . . . 0.0 110.475 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.26 -34.07 88.97 Favored Glycine 0 CA--C 1.52 0.383 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -65.26 -45.05 86.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.033 0.444 . . . . 0.0 110.505 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 92.5 mt -65.47 -28.66 44.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.246 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 24.3 mm-40 -91.31 -47.89 7.23 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -178.309 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -111.62 27.72 10.23 Favored Glycine 0 N--CA 1.469 0.871 0 N-CA-C 112.118 -0.393 . . . . 0.0 112.118 -178.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 45.84 -147.05 2.46 Favored Glycine 0 CA--C 1.524 0.628 0 C-N-CA 120.578 -0.82 . . . . 0.0 111.251 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.514 ' HE1' HD11 ' A' ' 18' ' ' ILE . 20.1 t-105 -50.61 -60.0 3.48 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.91 0.386 . . . . 0.0 111.321 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.3 m -50.66 -31.52 16.5 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.663 -179.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.78 -36.24 66.31 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . 0.408 ' C ' ' SD ' ' A' ' 17' ' ' MET . 13.4 tmm? -59.21 -47.85 83.8 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.718 0.294 . . . . 0.0 110.834 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.514 HD11 ' HE1' ' A' ' 14' ' ' TRP . 90.2 mt -62.5 -50.36 80.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.889 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -54.5 -41.68 69.9 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.727 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.08 -33.6 74.54 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.298 -0.721 . . . . 0.0 111.298 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -61.79 -48.31 81.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.799 0.333 . . . . 0.0 110.578 179.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -70.85 -30.91 67.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.629 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.73 126.03 0.12 Allowed Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 86.7 p . . . . . 0 C--O 1.219 -0.519 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.55 -179.872 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 59.4 tp -64.26 -50.73 66.81 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-O 120.862 0.363 . . . . 0.0 110.895 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -64.56 -46.95 80.57 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.769 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.14 -33.47 61.12 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -68.49 -46.13 70.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.707 0.289 . . . . 0.0 110.757 179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 85.5 mt -61.87 -51.8 68.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.837 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.31 -42.68 92.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.962 0.41 . . . . 0.0 110.619 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -62.64 -36.3 93.06 Favored Glycine 0 C--O 1.225 -0.411 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 40.2 t80 -62.72 -44.11 97.07 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.076 0.465 . . . . 0.0 110.746 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 87.8 mt -67.62 -27.78 39.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.927 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -89.61 -50.06 6.3 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -178.055 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.78 31.98 6.06 Favored Glycine 0 N--CA 1.464 0.539 0 N-CA-C 112.27 -0.332 . . . . 0.0 112.27 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.23 -145.23 1.83 Allowed Glycine 0 CA--C 1.525 0.687 0 C-N-CA 120.618 -0.801 . . . . 0.0 111.628 178.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . . . . . . . . . 30.8 t-105 -50.09 -62.45 1.57 Allowed 'General case' 0 C--N 1.32 -0.678 0 O-C-N 122.605 -0.35 . . . . 0.0 111.296 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.4 m -49.73 -35.34 21.76 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.849 0.357 . . . . 0.0 110.956 -179.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.54 -37.73 93.98 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 36.5 ttp -61.27 -40.94 95.95 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.494 179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.5 mm -61.7 -48.62 87.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.981 -179.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 14.8 t0 -60.72 -42.61 97.61 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.734 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -63.03 -37.2 94.56 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 73.9 t-105 -62.13 -45.85 91.62 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.725 0.298 . . . . 0.0 110.507 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -74.34 -34.21 63.35 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.715 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.93 1.1 46.27 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.4 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.97 -1.015 . . . . 0.0 110.613 -179.847 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 9.7 tp -65.22 -49.55 69.26 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.712 0.292 . . . . 0.0 111.121 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -63.64 -47.85 79.63 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.634 -179.36 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -57.92 -32.52 66.5 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -67.18 -46.38 74.13 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.619 0.247 . . . . 0.0 110.657 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 89.9 mt -60.52 -50.84 78.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.718 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -66.82 -42.45 85.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.625 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -63.92 -34.14 89.13 Favored Glycine 0 C--O 1.225 -0.459 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 35.0 t80 -65.35 -44.45 87.66 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.079 0.466 . . . . 0.0 110.558 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 89.4 mt -67.07 -27.33 39.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.064 -179.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -91.69 -48.46 6.81 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -178.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 16' ' ' GLY . . . -112.89 30.26 7.55 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 111.998 -0.441 . . . . 0.0 111.998 -178.57 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.11 -146.23 1.52 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.478 178.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' TRP . . . . . 0.534 ' HE1' HD11 ' A' ' 18' ' ' ILE . 28.8 t-105 -50.59 -61.82 1.96 Allowed 'General case' 0 C--N 1.32 -0.717 0 O-C-N 122.488 -0.419 . . . . 0.0 111.364 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.0 m -49.11 -32.35 9.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.775 -179.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 12' ' ' GLY . . . -70.73 -36.14 66.72 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' MET . . . . . . . . . . . . . 46.5 ttp -58.85 -45.35 90.29 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.756 0.312 . . . . 0.0 110.567 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.534 HD11 ' HE1' ' A' ' 14' ' ' TRP . 79.8 mt -63.9 -50.91 75.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.005 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -52.77 -41.98 64.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.721 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -69.43 -34.48 74.2 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 68.8 t-105 -63.34 -48.76 76.64 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.687 0.28 . . . . 0.0 110.535 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -74.2 -31.12 62.52 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.629 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.43 -66.01 1.31 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 12.4 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.037 -0.982 . . . . 0.0 110.586 179.967 . . . . . . . . 0 0 . 1 stop_ save_